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1. Summary 
Impaired fasting glucose and impaired glucose tolerance constitute pre-diabetic states 
that can continuously proceed to insulin resistance, the pre-eminent condition in type 2 
diabetes mellitus (T2DM). Further deterioration of glucose homeostasis can manifest 
itself as T2DM. The liver, the predominant source of glucose production, plays a central 
role in glucose homeostasis. Hepatic insulin resistance and steatosis result from elevated 
free fatty acid (FFA) blood levels and lead to increased hepatic glucose output. A simple 
way of increasing FFA blood levels is ensuring excessive caloric intake for the organism. 
Thus, diet-induced obesity is being used as a model for insulin resistance. Insulin 
regulates the carbohydrate and fat metabolism of the body. The complexity of the 
insulin signal transduction is reflected in the vast amount and diversity of involved 
signaling components. Mechanisms of insulin signaling are described including the 
beginning of insulin signaling, where the signaling molecules cytohesin 2 and 
cytohesin 3 come into play. Cytohesins are a subfamily of small guanine nucleotide 
exchange factors (GEF) that share a common domain organization. Inhibition of 
cytohesin 3, a regulator of hepatic insulin signaling, was shown to lead to hepatic 
insulin resistance.  
This dissertation examines effects of high-fat diet feeding on cytohesin 2 and 
cytohesin 3 mRNA steady-state expression levels and cytohesin 3 protein expression 
levels in murine liver tissue using quantitative real-time polymerase chain reaction (qRT-
PCR) and Western blot analysis. I analyzed livers of mice derived from a study in which 
effects of high-fat diet on the cardiovascular system was analyzed in a mouse model. 
Mice were fed control (C), high-fat (HF), and very high-fat (VHF) diets for 15 weeks, 
which resulted in overweight and impaired glucose tolerance in the groups with 
elevated fat intake. Relative expression levels for cytohesin 2, cytohesin 3 and 
β2 microglobulin (as house keeping gene) were determined by qRT-PCR. Correct primer 
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design for cytohesin 2 was controlled by sequencing of the qRT-PCR product. The primer 
product of cytohesin 3 had to be inserted into a plasmid before it could be sequenced 
successfully. Proteins were also extracted from the mouse liver samples, separated on 
SDS-PAGE gel and immunoblotted with anti-cytohesin 2 and cytohesin 3 antibodies and 
anti-p44/42 antibodies. 
I found that there is approximately seven times more cytohesin 2 than cytohesin 3 
mRNA expressed in murine livers. Only the VHF group exhibited significant but small 
increases in cytohesin 2 and cytohesin 3 mRNA expression levels compared with control 
diet fed mice (24 and 37 %, respectively). Cytohesin 3 protein expression levels were not 
affected by high-fat diet feeding. 
In summary in light of current T2DM treatment recommendations and fading scientific 
interest in cytohesins with respect to insulin signaling, my data support the notion that 
expressional control of cytohesins is not essential for insulin signaling in the conditions 
analyzed. Literature data suggest that ectopic fat accumulation (especially in the liver) 
and chronic low-grade inflammation generated by adipose tissue macrophages are 
important factors that contribute to high-fat diet-induced impaired glucose tolerance 
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2. Introduction 
2.0. Type 2 Diabetes Mellitus 
All mammalian cells use glucose as a fuel for their basic functions [1]. In order to 
maintain stable glucose levels, an intricate system of neural, hormonal and direct 
nutrient responses are initiated after stress (exercise or hypoglycemia) or a meal [1]. 
Diabetes mellitus is a syndrome encompassing heterogeneous diseases that share a 
disorder of glucose metabolism with chronic hyperglycemia as consequence of absolute 
or relative, i.e. functional, insulin insufficiency [2]. Impaired fasting glucose and 
impaired glucose tolerance constitute pre-diabetic states that can proceed to insulin 
resistance, which means that target tissues do not respond effectively to normal insulin 
levels. Inhibition of the insulin signaling pathway leads to insulin resistance. Diabetes 
mellitus is mainly divided in type 1 and type 2 diabetes. Type 1 diabetes is characterized 
by primary destruction of pancreatic Langerhans β-cells, the production and secretory 
site of insulin [2]. Insulin resistance is the pre-eminent condition in type 2 diabetes 
mellitus (T2DM) and can lead to secondary failure of Langerhans β-cells. Diabetes is 
generally associated with insulin resistance in the main target tissues, including liver, 
muscle, and fat but the hypothalamus is involved, also [3]. The etiology of T2DM consists 
of multiple genetic and environmental factors (foremost overnutrition and lack of 
exercise) [2, 4]. 
2.0.1. Obesity, Liver and T2DM 
Obesity is defined in the ICD-10-code by a body mass index (BMI) greater than 30 kg/m2, 
whereas overweight starts at a BMI greater than 25 kg/m2. The BMI is calculated by 
dividing body weight in kg by body height in m squared. The etiology or cause of 
obesity is an imbalance between the energy ingested and the energy expended [5]. The 
excess energy is stored in fat cells, adipocytes, that enlarge and/or increase in 
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number [5]. It is this hyperplasia and hypertrophy of fat cells that is the pathological 
lesion of obesity [5]. The weight or mass of extra fat, and the increased secretion of free 
fatty acids (FFA) and numerous peptides from enlarged adipocytes contribute to the 
clinical problems associated with obesity [5]. Among endocrine changes associated with 
obesity are decreased levels of growth hormone and adiponectin and increases in levels 
of insulin, leptin, thyroid stimulating hormone (in the upper normal range), androgens, 
progesterone, interleukin 6 (IL-6), ACTH/cortisol, and sympathetic nervous system 
activity [5]. IL-6, secreted in adipose tissue, is an important mediator of hepatic insulin 
resistance [6]. Obesity and increased fat mass are associated with adipose tissue 
inflammation [7]. Obese subjects have generally been found to be leptin resistant, thus 
the promoting of satiation in the hypothalamus is dysfunctional [8]. An intact functional 
leptin axis is necessary to prevent accumulation of lipids in non-adipose tissues that are 
not adapted for triglyceride storage [9]. Still, weight loss is associated with a reduction 
in adipocyte size, macrophage infiltration, and secretion of inflammatory factors, and 
an increase in adiponectin secretion [9]. Besides increased insulin secretion, insulin 
resistance results from obesity [5]. But increased insulin levels are found only before the 
endocrine production of insulin by the pancreas fails.  
T2DM is strongly associated with overweight in both genders in all ethnic groups and 
typically is preceded by obesity [5, 10]. The risk of T2DM increases with the degree and 
duration of overweight [5]. Weight loss or moderating weight gain over years reduces 
the risk of developing diabetes [5]. There is evidence that obese individuals differ 
substantially during rest in brain networks related to reward and food regulation 
compared with lean subjects because obesity and insulin levels influence brain 
function [11]. Studies demonstrate that increasing lipid oxidation in the liver prevents 
hepatic steatosis and insulin resistance [12]. Important aspects in T2DM treatment are 
lifestyle changes: foremost weight reduction through calorie reduction in overweight 
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patients and increased, appropriately prescribed physical exercise which increases 
insulin sensitivity in skeletal muscles [13, 14].  
The amount of fat in a meal required to result in significant elevations in plasma 
triglycerides, the hallmark of postprandial lipemia, is in the order of 30–50 g, well 
within the range of many usual meals [15]. It seems that the higher the BMI the greater 
the postprandial lipemic response [16]. Interestingly, fat quality appears to have a 
greater impact on postprandial lipemia than fat quantity, because ingested saturated 
fatty acids (SFA) have a greater impact on the postprandial triglyceride response than 
monounsaturated fatty acids (MUFA) and n-6 polyunsaturated fatty acids (PUFA), which 
contribute more to lipemia than n-3 PUFA [15]. But in the usual diet SFA and MUFA, not 
PUFA, are the most abundant fatty acids [15]. Reducing intake of TFA, as is 
recommended by the American Diabetes Association, lowers LDL cholesterol and 
increases HDL cholesterol [14]. Therefore, improving fat quality should be considered 
part of a dietary lifestyle strategy to prevent or manage T2DM [17]. 
The magnitude of the risk of diabetes contributed by obesity appears to be much 
greater than that imparted by physical inactivity [15]. A one-year long lifestyle (diet and 
exercise) intervention in T2DM patients lead to greatly improved levels of peripheral 
insulin sensitivity, fasting glucose, and FFA in parallel to significant weight and fat loss, 
improvement in adipose tissue distribution, and decrease in hepatic fat [18]. It appears 
that the degree of adipose tissue inflammation rather than the level of adiposity is 
more closely related to liver fat [9]. The changes in peripheral insulin sensitivity were 
best predicted by the overall change in weight and fat mass; interestingly, the only 
regional fat measure independently predicting metabolic improvements was the 
decrease in hepatic fat [18].  
The liver is the predominant source of glucose production, with small contributions by 
the kidney and the gut while peripheral tissues (skeletal muscle and fat) and the central 
nervous system remove glucose from the plasma especially [1]. While an insulin sensitive 
Introduction 
 
- 11 - 
glucose transporter (GLUT4) is rate limiting in several peripheral tissues (muscle, fat), in 
the liver, however, glucose moves freely across the plasma membrane in either 
direction [1]. A positive correlation between anti-apoptotic mediators and hepatic 
mRNA levels of insulin receptor substrate 1 and 2 (IRS1 and IRS2) was noted, indicating 
that enhanced hepatocyte apoptosis in non-alcoholic steatohepatitis (NASH) and 
chronic hepatitis C virus (HCV) infection is closely associated with impairment of the 
hepatic insulin signaling pathway [19]. Moreover, there is a negative correlation 
between hepatic mRNA levels of IRS1/IRS2 and type I collagen, indicating that disruption 
of hepatic insulin signaling is associated with increased liver fibrogenesis in non-
alcoholic fatty liver disease (NAFLD) and HCV infection [19]. Lemoine and Serfati 
consider insulin resistance being the cornerstone in the development of NAFLD, which 
includes simple steatosis and NASH [20]. But Valverde and Gonzalez-Rodriguez 
demonstrated that the hepatic insulin signaling cascade is normal in patients with 
simple steatosis; this could indicate that hepatic fat accumulation precedes disruption of 
hepatic insulin signaling at the molecular level [19]. The insulin-resistant state that is so 
common in human obesity probably reflects the effects of increased release of FFA from 
fat cells that are then stored in the liver or muscle [5]. Further was shown that fat 
accumulation in the liver is associated with features of the metabolic syndrome, 
regardless of intra-abdominal fat accumulation, fat accumulation in skeletal muscle, or 
BMI [21-23]. Hypertension, a widespread disease, is strongly associated with T2DM, 
impaired glucose tolerance, hypertriglyceridemia, and hypercholesterolemia [5].  
The leading hypothesized mechanisms to explain insulin resistance and islet β-cell 
dysfunction in T2DM have been oxidative stress, endoplasmic reticulum stress, amyloid 
deposition in the pancreas, ectopic lipid deposition in the muscle, liver and pancreas, 
and lipotoxicity (toxic effects of elevated levels of FFA) and glucotoxicity (toxic effects of 
hyperglycemia) [24]. All of these stresses can be caused by overnutrition [24]. It is 
noteworthy, that each of these cellular stresses is also thought to either induce an 
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inflammatory response or to be exacerbated by or associated with inflammation [24]. 
Thus, both, obesity and T2DM, have an inflammatory component [24].  
Figure 1. Effects of diet-induced obesity leading to T2DM in adult rodents. Adapted 
from [10]. 
The effects of diet-induced obesity (DIO) in rodents are summarized in figure 1: 
In the pancreas, DIO leads to a decreased pancreatic enzyme activity, followed by 
pancreatic dysfunction and decreased insulin secretion. Finally the progression to 
hyperglycemia and T2DM ensues.  
Obesity leads to adipocyte hypertrophy and elevated blood concentrations of  
non-esterified FFA. These FFA are deposited in the liver and in skeletal muscle, leading 
to steatosis and insulin resistance of these tissues. The insulin resistance and the reduced 
glucose uptake in skeletal muscle are followed by hyperglycemia and T2DM. 
DIO results in hepatic steatosis, also. This is succeeded by hepatic insulin resistance and 
an increased hepatic glucose output, which is followed by hyperglycemia and T2DM. 
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2.0.2. Metabolic Syndrome and T2DM 
Diabetes mellitus is constituent of the metabolic syndrome. But internationally no 
agreement exists upon the criteria for metabolic syndrome [25]. Even the inclusion of 
diabetes mellitus in these criteria is being questioned [25]. Moreover, the concept of 
metabolic syndrome itself is subject to limitations, because the treatment of metabolic 
syndrome is no different than the treatment for each of its components, and the 
medical value of diagnosing it is unclear [25]. 
2.0.3. Epidemiology and Costs of T2DM 
Type 1 diabetes affects 5% of the overall diabetic patients; the rest of diabetic 
syndromes, of which T2DM forms the major group, represent 95% of the entire diabetic 
population [26]. T2DM affects over 5% of the population in Western societies [26]. T2DM 
used to be referred to as adult-onset diabetes. Today this name has become obsolete, 
since the condition is being diagnosed in children more frequently in recent years, 
especially in obese children [27, 28].  
Between 1992 and 2007 there was a considerable increase from 30.3% to 37.3% of the 
Swiss population that suffered from overweight [29]. Based on data from 2007 and 2008 
the prevalence of adult overweight in the USA was 68.3% – almost doubling the 
prevalence in the Swiss population [30]. The most recent estimate for overweight 
prevalence in the U.S. amounted to 69.2% [31]. The total (obesity-linked) disease costs 
of overweight and obesity in Switzerland more than doubled from CHF 2.648 billions 
(cost basis 2001) to CHF 5.755 billions (cost basis 2006) [29]. For the cost estimate 
reported in 2004 T2DM contributed 54.5% of the total obesity-linked disease 
costs [29].The total attributable cost of T2DM amounted to CHF 2.070 billions in 2006 
(36% of the total obesity-linked disease costs) [29]. From 26 reported obesity-associated 
diseases, T2DM is the leading comorbidity carrying the highest risk (relative risk ≥ 3.4) of 
developing in the course of body weight increase [29]. Clearly, the growing prevalence 
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of obesity is the major factor driving the increasing prevalence of T2DM [29]. 
Consequently, the number of adults with T2DM is predicted to almost double on a 
worldwide scale, from approximately 171 million in 2000 to 366 million by the year 
2030 [29]. It can be expected that the prevalence of T2DM in Switzerland in the coming 
years will increase in parallel with the observed increase in prevalence of overweight 
and obesity in the period from 1992 to 2007 [29]. In Switzerland health care costs 
amounted to 10.8% of the national gross domestic product (NGDP) of CHF 486.2 billions 
in 2006 [29]. The total costs of T2DM added up to 4.3‰ of the NGDP or 2.3% of health 
care costs [29]. In comparison, in the USA prevalence of diabetes continues to grow, too, 
leading to a higher economic burden [32]. There, approximately 10% of health care 
costs were attributed to diabetes in 2007 [32]. This relatively high quota in health care 
costs can be explained, at least in part, with the high prevalence in overweight. 
2.0.4. T2DM and Pregnancy 
As obesity reaches pandemic proportions, of particular concern is the increase in obesity 
among women of reproductive age [33]. Because there is strong evidence from both 
human and animal studies that the early environment and in particular early nutrition 
play an important role [34]. So individuals exposed in utero to either maternal obesity 
or gestational diabetes mellitus have increased risk of developing T2DM, hypertension, 
obesity and other features of metabolic syndrome in later life [33]. But poor growth 
in utero is associated with increased risk of developing diseases such as T2DM in later 
life, also [34]. Additionally to T2DM, similar relationships have been observed linking 
birth weight to other conditions such as cardiovascular disease, insulin resistance, and 
other features of metabolic syndrome [34]. Interestingly, the detrimental effects of poor 
fetal growth on long-term metabolic health appear to be exaggerated if followed by 
accelerated postnatal growth and/or obesity [10, 34]. Concerning the risk of obesity, 
accelerated postnatal growth appears to be particularly detrimental even in individuals 
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who had a normal birth weight [34]. Human twin studies provide strong evidence for 
the importance of a nongenetic intrauterine factor in the development of T2DM in later 
life [34]. It has been shown that nutritional influences in early life can induce permanent 
alterations in epigenetic and histone modifications [34]. Studies revealed that 
individuals who were exposed to famine in utero during the Dutch Hunger Winter had 
altered methylation of the insulin-like growth factor 2 gene in white blood cells in 
adulthood – thus maternal diet can influence epigenetic marks in humans [34]. An 
alternative mechanism by which environmental factors at critical periods of 
development could have long-term phenotypic consequences is through permanent 
structural changes in key organs [34]. If a certain nutrient or hormone is essential at a 
critical period of development for growth and differentiation of a tissue, inappropriate 
levels of this factor will have permanent structural consequences [34]. Taken together, 
there is now little doubt that fetal and early postnatal life are important time periods 
for the determination of future risk of T2DM, obesity, and other features of the 
metabolic syndrome [34].  
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2.1. Insulin Signaling 
2.1.1. Insulin 
Insulin, an anabolic hormone, is produced and secreted into the bloodstream by the 
Langerhans β-cells in the endocrine pancreas islets. The most important stimulus for insulin 
synthesis and secretion is an increase in blood sugar level [35]. Its function constitutes the 
regulation of the carbohydrate and the fat metabolism of the body. It promotes processes 
that affect a decrease of blood sugar level, such as stimulating glucose uptake in skeletal 
muscle and the liver, supporting glycogenesis and inhibiting glycogenolysis, promoting 
lipogenesis and inhibiting lipolysis, and stimulating protein synthesis (figure 2). Insulin 
stimulates lipogenesis in fat tissue, as well as the liver, by activating acetyl-coA carboxylase, 
the rate-limiting enzyme in fatty acid synthesis [8]. Upon fasting, lipogenesis is inhibited and 
acetyl-coA carboxylase is inactivated as a result of low insulin levels, as well as the effects of 
catecholamines and glucagon [8]. 
 
Figure 2. Insulin action in main target tissues. ↑ up-regulation, ↓ down-regulation. 
Insulin has a higher potency in suppressing glycogenolysis versus gluconeogenesis, 
yet increased gluconeogenesis is the major contributor to fasting hyperglycemia in humans 
who have T2DM [36]. Insulin also regulates nonmetabolic processes such as cell growth and 
differentiation and is a growth factor during fetal development [3, 8]. Insulin signaling has 
Introduction 
 
- 17 - 
been found to regulate dopamine neurotransmission and to affect the ability of drugs that 
target the dopamine system to exert their neurochemical and behavioral effects [37]. Main 
target tissues of insulin are skeletal muscles, fat tissue and the liver, but other tissues, i.e. 
hypothalamus, are influenced by insulin, also [6, 35]. The effects of insulin on glycogenesis 
and glycogenolysis are antagonised by glucagon [35]. In contrast to other mammals (such as 
humans and guinea pigs), murine rodents express two insulin genes instead of one [38]. 
Oral glucose uptake in a healthy mammal is followed by typical changes in blood glucose 
concentration: A rise in blood glucose in the absorptive phase stimulates the release of insulin 
from pancreatic β-cells and hepatic glucose output is inhibited through the Akt/FOXO1 
signaling pathway by suppressing transcriptional activation of genes encoding enzymes in the 
gluconeogenic pathway [1, 8, 19]. Half an hour to an hour after glucose ingestion the blood 
glucose zenith is reached [1]. Glucose removal processes operating at maximal rates combined 
with inhibited hepatic glucose output lead to a rapid fall of blood glucose, reaching levels 
below the original baseline and finally settling at baseline level [1]. This hypoglycemic phase 
is due to the inertia of the regulatory mechanisms because, in general, the higher the 
glycemia the greater the subsequent hypoglycemia [1]. 
2.1.2. Mechanisms of Insulin Signaling 
The insulin signaling cascade is complexly build, which is illustrated by the fact that even in 
the first three signaling steps in the metabolic pathway of insulin action (from insulin 
receptor (IR) to insulin receptor substrate (IRS) to Akt), there are at least 288 combinations of 
signaling molecules [3]. Taking into account other pathways and those not yet discovered, the 
number of signaling combinations probably exceeds 1000 [3]. Thus, in theory, diminishing the 
activity of any single component of the insulin signaling cascade or any combination of 
components may produce a distinct type of insulin resistance with its own molecular 
signature [3]. Further, all signaling components can undergo posttranslational modifications 
that decrease or increase their activity [3]. On top of that the signaling pathways of insulin 
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and insulin-like growth factor 1 (IGF1) are very similar [8]. This is reflected in the existence of 
insulin/IGF hybrid receptors [39].  
There are several known insulin signaling pathways. For all of them, the first step in insulin 
signaling is the docking of insulin to the IR [19]. This induces a conformational change, which 
activates the tyrosine kinase activity on the cytoplasmic part of the cell and results in 
autophosphorylation of the IR and phosphorylation of other protein molecules [8, 19]. The 
activation of the IR by insulin results in the tyrosine phosphorylation of the immediate 
substrates of the insulin receptor kinase, members of the IRS family, IRS1 and IRS2 (figure 3, in 
red) [6, 8, 19, 40]. This initiates two major signaling cascades: the mitogenic and the metabolic 
pathways (figure 3, green and blue pathways, respectively) [33, 41]. The IR and the IRS 
proteins share common mechanisms of regulation: they are activated by tyrosine 
phosphorylation, and they are negatively regulated by protein tyrosine phosphatases (PTP), 
serine phosphorylation and ligand-induced down-regulation [41].  
Introduction 
 
- 19 - 
 
Figure 3. Signaling pathways for the main effects of insulin. Unbroken arrows stand for signal transduction. Dotted arrows imply translocation to the 
plasma membrane. Interrupted lines signify signaling inhibition. Cytohesin domains are explained in figure 4. ↑ up-regulation, ↓ down-regulation.  
Adapted from [3, 8, 39, 42-44]
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2.1.2.1. Increasing Glucose Uptake 
Insulin stimulates cellular glucose uptake through the following pathway: 
Phosphorylation of IRS proteins on tyrosine residues results in the recruitment of 
signaling molecules to these proteins [8]. This recruitment is typically mediated by 
phosphotyrosine binding motifs such as SH2 (Src homology 2) domains and allows the 
binding and activation of the phosphatidylinositol 3-kinase (PI3K) [3, 6, 8, 19]. Active PI3K 
exists as a heterodimer, consisting of a p110 catalytic subunit, of which there are three 
isoforms, and a regulatory subunit, of which there are eight known isoforms, p85α 
being the most abundant and ubiquitously expressed of them [3]. If the regulatory 
subunits of PI3K (p50α, p55α, p85α and β) are increased above physiological levels, they 
can act as inhibitors of the normal dimeric form of the enzyme [3]. p85α contains 
multiple domains that may mediate interactions with other proteins, including a src 
homology region 3 (SH3) domain, a bcr homology domain flanked by two proline-rich 
regions, and two SH2 domains that flank the p110 catalytic subunit-binding region [3]. In 
response to insulin, IRS1 and IRS2, as well as the p85 subunit of PI3K, migrate from the 
intracellular membranes to the cytosol [43]. Recruitment of PI3K to IRS1 results in the 
phosphorylation of membrane phosphoinositides, generating the lipid second 
messenger phosphatidylinositol-3,4,5-triphosphate (PIP3) in the cell, which leads to 
membrane recruitment through its pleckstrin homology (PH) domain and 
phosphorylation and activation of a downstream signaling kinase, the serine/ 
threonine kinase Akt, via the 3-phosphoinositide-dependent protein kinase 1  
(PDK1) [3, 6, 8, 26, 39-41]. In mammalian cells, PIP3 is transiently accumulated in plasma 
membranes following activation of PI3K [45]. Negative regulation of the PI3K pathway is 
primarily accomplished through the action of the phosphatase and tensin homologue 
(PTEN) tumor suppressor proteins, but other phosphatases, such as SH2 domain-
containing inositol 5’phosphatase (SHIP)-1 and SHIP-2, play a role, too [46]. PDK1 and 
PDK2 are recruited to the plasma membrane by PIP3 and they are activated by 
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phosphatidylinositol 3-phosphates, particularly PIP3 [3, 26, 43]. Akt contains an amino-
terminal PH domain that serves to target the protein to the membrane for activation, 
which depends on the phosphorylation of two of its residues [46]. Akt is not only 
phosphorylated and thusly activated by PDK1 but by the mammalian target of 
rapamycin (mTOR) complex 2 (mTORC2), also, which used to be referred to as PDK2 [46]. 
Once activated, Akt leaves the cell membrane to phosphorylate intracellular substrates, 
which can be located in the nucleus [46]. One of these substrates is Akt substrate of 160 
kDa (AS160), also known as TBC1D4 [3, 39, 47]. Phosphorylation by Akt inhibits the Rab-
GTPase-activating protein AS160, resulting in activation of Rab small GTPases required 
for translocation of GLUT4, the predominant glucose transporter isoform expressed in 
muscle and fat tissues, from GLUT4 storage vesicles to the plasma membrane [40, 43]. 
Docking and fusion of GLUT4 storage vesicles with the plasma membrane is regulated 
by insulin [40]. An increase in the amount of GLUT4 at the plasma membrane results in 
increased glucose uptake (figure 3, blue pathway).  
In adipocytes it is suggested that the protein pleckstrin homology-like domain family B 
member 1 (PHLDB1) is an insulin signaling component involved in the regulation of Akt 
activation and its downstream signaling (not shown in figure 3) [48]. The levels of 
PHLDB1 protein influence a major biological effect of insulin in adipocytes, GLUT4 
translocation and glucose uptake [48]. These effects appear to be exerted at the level of 
Akt activation downstream of the IR/IRS1/PI3K pathway activated by insulin [48]. 
There is an alternative pathway resulting in enhanced glucose uptake: PI3K also 
activates the atypical forms of protein kinase C (aPKC), including PKCλ and PKCζ [3, 33]. 
Like Akt, the aPKC appear to be important in mediating insulin-stimulated glucose 
uptake, since their over-expression results in increased translocation of GLUT4 to the 
plasma membrane [3]. aPKC phosphorylate and thus inhibit AS160, which leads to 
enhanced GLUT4 incorporation into the plasma membrane as described above  
(figure 3) [39].  
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2.1.2.2. Increasing Lipid Synthesis 
But aPKC also activate the transcription factor sterol regulatory element-binding 
protein (SREBP1c) (figure 3, yellow pathway) [3]. It is the dominant isoform in liver and 
adipose tissue of the SREBP family of three nuclear transcription factors [3]. Many of 
insulin’s effects on lipogenesis appear to be mediated via SREBP1c [3]. SREBP1c can 
activate the entire program of MUFA synthesis (resulting in increased lipid synthesis), 
appears to be involved (to a lesser extent than FOXO1) in the regulation of 
gluconeogenic genes, and can suppress transcription of IRS2 [3]. Mixed insulin sensitivity 
and resistance in the liver – that is, decreasing activation of Akt and the ability of insulin 
to suppress glucose production, while increasing activation of SREBP1c and lipogenesis – 
may produce glucose intolerance and hepatic steatosis [3]. 
2.1.2.3. Increasing Glycogen Synthesis 
Activated Akt controls a variety of downstream responses depending on cell type and 
substrate (figure 3) [39]. Glycogen synthase kinase (GSK) and mTOR, which lead to 
stimulation of glycogen and protein synthesis, respectively, are downstream targets of 
Akt [3, 6, 8]. Akt phosphorylates glycogen synthase kinase 3 (GSK3), deactivating it [3]. 
Deactivation of GSK3 leads to derepression, i.e. activation of glycogen synthase, which 
results in a stimulation of glycogen synthesis (figure 3, pink pathway) [3]. But it was 
found that allosteric regulation of glycogen synthase by glucose 6-phosphate, rather 
than covalent regulation by the Akt/GSK3 cascade, is the major mechanism by which 
insulin stimulates muscle glycogen synthesis in vivo [39]. 
2.1.2.4. Increasing Protein Synthesis 
Tuberous sclerosis complex 2 (TSC2), when complexed with its binding partner TSC1, acts 
as a GTPase activating protein (GAP) for the RAS-related small G protein Rheb, which is 
a potent activator of mTOR Complex 1 (mTORC1) [49]. Akt mediated direct 
phosphorylation of TSC2 within an intracellular membrane compartment and 
subsequent translocation to the cytosol, where it is bound by 14-3-3, relieves its ability to 
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act as a GAP for Rheb within cells (through spatial segregation but without loss of its 
intrinsic GAP activity toward Rheb), allowing Rheb-GTP to accumulate and activate 
mTORC1 (figure 3, brown pathway) [46, 49, 50]. Thus, Akt-induced multi-site 
phosphorylation and destabilization (inhibition) of the Rheb GTPase activating 
TSC1/TSC2 complex, which inhibits mTOR, is necessary for mTORC1 activation [3, 6, 39, 49]. 
Akt activates mTORC1 by phosphorylating TSC2 and PRAS40 on sites that mediate 14-3-3 
binding and that relieve the inhibitory effects of these proteins [44]. The TSC1/TSC2 
complex dissociates after phosphorylation by Akt [50]. In mTORC1, mTOR associates with 
two highly conserved proteins Raptor (Regulatory associated protein of mTOR), a 
protein scaffold that recruits downstream substrates of mTOR, such as the S6 kinase and 
4EBP1, and mLST8, a member of the Lethal-with-Sec-Thirteen gene family, plus PRAS40, 
a repressor of mTOR activity, and Deptor [44, 46, 51]. The mTOR pathway integrates 
insulin and amino acids/nutrient signaling pathways [6]. There is evidence that mTORC1 
activation is both necessary and sufficient to stimulate expression of the adipogenic 
transcription factor PPARγ (peroxisome proliferator-activated receptor γ) and adipocyte 
differentiation [49]. While mTORC1 is clearly downstream of Akt, its activation can lead 
to feedback inhibition of insulin signaling to Akt through effects on the IRS proteins 
and the ensuing attenuation of PI3K activation (not shown in figure 3) [49]. mTORC1-
mediated phosphorylation of S6K1/2 (ribosomal protein S6 kinase, also known as p70 S6 
kinase or p70S6K) and 4EBP1/2 (eukaryotic translation initiation factor 4E-binding 
protein 1 and 2) stimulates mRNA translation and, ultimately, anabolic processes, such as 
cell growth and proliferation (figure 3, brown pathway) [51]. p70 S6 kinase catalyzes the 
phosphorylation of the S6 protein, a component of the 40S subunit of eukaryotic 
ribosomes [52]. 
A second mTOR-containing protein complex (mTORC2) consists of mTOR, rictor 
(rapamycin-insensitive companion of mTOR; also known as mAVO3), Sin1  
(stress-activated-protein-kinase-interacting protein 1, also known as mSin1 or MIP1), 
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mLST8, Deptor, and protor (protein observed with rictor) [51, 53, 54]. mTORC2 lies 
upstream of Akt and contributes to Akt activation by insulin and growth factors by 
serine phosphorylation in its hydrophobic regulatory motif (figure 3, blue pathway), 
besides it is also involved in the phosphorylation of a similar motif of protein kinase C α 
(PKCα) [49, 51]. The phosphorylation of a second conserved motif on Akt and PKCα, 
referred to as the turn motif, is also dependent on mTORC2 [51]. Thus, mTOR lies both 
upstream (mTORC2) and downstream (mTORC1) of Akt [51]. Experimental data 
demonstrate that the TSC1-TSC2 complex promotes mTORC2 activity in a manner that is 
independent of Rheb, mTORC1, and mTORC1-mediated feedback effects on PI3K [51]. By 
contributing to mTORC2 activation, and through its inhibition of mTORC1-dependent 
feedback mechanisms, the TSC1-TSC2 complex acts to divert Akt signaling from mTORC1 
activation into its other downstream branches [51].  
2.1.2.5. Inhibition of Gluconeogenesis and of Apoptosis by FOXO 
Activated Akt can translocate into the nucleus where it phosphorylates the  
forkhead-box transcription factors FOXO1 and FOXO3 in vertebrates, leading to their 
deactivation and nuclear exclusion and eventual ubiquitination-dependent proteasomal 
degradation [3, 8, 55, 56]. FOXO1 is the molecular link between Akt phosphorylation and 
gluconeogenic gene expression [19]. FOXO3, in its unphosphorylated state, is a nuclear 
transcriptional regulator of genes involved in apoptosis, proliferation and the control of 
oxidative phosphorylation [56]. Phosphorylation of FOXO1 leads to its exclusion from the 
nucleus, preventing it from activating transcription of various genes, such as 
phosphoenolpyruvate carboxykinase and glucose 6-phosphatase, two important 
enzymes in gluconeogenesis [3, 8, 57]. Nuclear export and cytoplasmic retention of FOXO 
proteins are facilitated by the binding to 14-3-3 proteins, which promote cell 
proliferation and survival (figure 3, cyan and lilac pathways, respectively) [44, 58]. 
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2.1.2.6. Inhibition of Apoptosis by BAD 
Also, failure of activation of Akt leads to the insulin signal impairment on BAD, a  
pro-apoptotic BCL-2 family member [26, 59]. Akt generates a 14-3-3 docking site on  
BAD [44]. BAD activity is antagonized by 14-3-3 proteins by retaining BAD in the 
cytoplasm and preventing its translocation to its site of action, the mitochondria (figure 
3, gray pathway) [44]. Glucose deprivation results in dephosphorylation of BAD and  
BAD-dependent cell death [59]. Moreover, the phosphorylation status of BAD helps 
regulate glucokinase activity [59]. 
2.1.2.7. Increasing Transcription of Mitogenic Genes 
The mitogenic effects of insulin are modulated by the mitogen-activated protein kinase 
(MAPK) pathway, which controls cell growth, differentiation and survival [8, 19, 33, 41]. 
Activation of this pathway occurs due to the ability of insulin-stimulated IRS1 to bind 
the SH2 domain of the adaptor molecule growth factor receptor-bound protein 2 
(GRB2) [3, 8, 39]. GRB2 is recruited to the receptor via its SH2 domain [60]. This, in turn, 
recruits and activates the guanine nucleotide exchange factor SOS (son of sevenless 
homolog) to the plasma membrane next to membrane-bound G-proteins RAS, which it 
activates [3, 8, 52, 60]. Also, the pathway is initiated by recruitment of the 
adaptor/guanine nucleotide exchange factor complex GRB2/SOS to phosphorylated Src 
homology 2 domain containing transforming protein (SHC) (figure 3, green 
pathway) [39]. It is unclear whether SHC-bound and IRS-bound GRB2/SOS complexes are 
equally effective activators of RAS, given the differences in their abundance, subcellular 
localization and potential co-recruitment of additional components [39]. Activated (GTP-
bound) RAS in turn sequentially phosphorylates and activates the kinase RAF, a MAPK 
kinase kinase (MKKK), which it recruits to the membrane, the MAPK kinase 1 and 2 
(MEK1/2), and the MAPK ERK1 and ERK2 (extra cellular signal regulated kinase 1  
and 2) [3, 39, 52, 60]. Binding of 14-3-3 proteins to a site in the carboxy-terminal region of 
RAF proteins is needed for full catalytic activity, which is responsible for 
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serine/threonine phosphorylation of MEK1 [44, 46]. MAPK can phosphorylate substrates 
in the cytoplasm (for example, increasing protein synthesis via p90RSK (p90 ribosomal 
protein S6 kinase) and p70S6K, respectively) or translocate to the nucleus to 
phosphorylate transcription factors such as Elk-1 [3]. Scaffold proteins play a role in 
coordinating this cascade, and may influence cellular responses through effects on 
signal intensity and duration, localization of complexes and recruitment of modulatory 
proteins such as phosphatases and ubiquitin ligases [39].  
2.1.3. Insulin Receptor 
The IR, a receptor tyrosine kinase consisting of a tetramer of extra cellular α-subunits 
(capable of insulin binding) and intracellular β-subunits (with intrinsic tyrosine kinase 
activity), exists as two isoforms differing by the presence (IR-B) or absence (IR-A) of 12 
amino acids at the carboxyl terminus of the α-subunit, as a result of alternative splicing 
of the sequence encoded by exon 11 [3, 39-41]. In the type 1 insulin-like growth factor 
receptor (IGFR), the corresponding sequence is always lacking [39]. Ligand binding of 
the α-subunits allows the β-subunits to transphosphorylate one another, further 
increasing their kinase activity [3]. Serine phosphorylation of the IR decreases its kinase 
activity [3]. IR-B is the more abundant isoform in muscle, liver and fat tissue [39]. Each 
isoform has a different affinity for insulin and IGF1 [41]. Insulin binds with similar 
affinity to both isoforms, but IGF, and particularly IGF2, have greater affinity for IR-A 
than IR-B, such that IR-A is a significant mediator of IGF2 action at physiological 
concentrations [39]. Additionally, both IR isoforms can form hybrids with IGFR as well as 
with each other [39]. Hetero-dimerisation occurs with similar efficiency to homo-
dimerisation, so that if one receptor is expressed in excess, the less abundant is 
assembled largely into hybrids [39]. Hybrids bind IGF with similar affinity to IGFR, but 
bind insulin with substantially lower affinity than IR [39]. It is unclear whether hybrid 
receptors have a distinct physiological role [39]. Despite the dimeric receptor structure, 
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only a single molecule of ligand can make all the contacts required to bind with high 
affinity and binding [39]. 
Functionally, the IR behaves like a classical allosteric enzyme in which the α-subunit, 
when not bound to insulin, inhibits the tyrosine-kinase activity that is intrinsic to the  
β-subunit [41]. As well as initiating intracellular signaling, ligand-induced  
auto-phosphorylation triggers internalization of ligand/receptor complexes, leading to 
dissociation and degradation of ligand in the intracellular endosome/lysosome system 
and inactivation and recycling of receptors [8, 39]. During this trafficking through the 
cell in endosomes, the receptor remains active and so increased or more rapid 
trafficking could result in attenuated signaling [8]. Interfering with the down-regulation 
of the receptor (as occurs in cells with mutant forms of the receptor) or the ubiquitin 
protein ligase (thus preventing their interaction), results in increased levels of the 
receptor [8]. However, receptor internalization may also play an active role in signaling, 
particularly via the MAPK pathway [39]. Internalized receptors are inactivated by  
phosphotyrosine-specific phosphatases, particularly PTP1B, which is localized to the 
cytosolic face of the endoplasmic reticulum [39]. 
The IR plays a direct role in the β-cell growth (it is critical in triggering β-cell hyperplasia 
in response to hepatic insulin resistance), and it is part of the onset of the glucose 
sensing machinery involved in the insulin secretion [26]. Besides of the IRS family targets 
of the IR tyrosine kinase include SHC, CBL (Casitas B-lineage lymphoma protooncogene), 
p62dok (Docking protein 1), and GRB2-associated binder-1 (Gab-1) [3]. Once 
phosphorylated, these substrates act as docking molecules for proteins that contain SH2 
domains, which in turn become activated or associate with other downstream signaling 
molecules [3]. 
The IR is a polymorphic gene in humans with several known mutations [26]. But 
mutations in the IR account for only 1% of the non-insulin-dependent diabetics [26]. 
Thus these pathologies that result in the lack of functioning IR, which among others 
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generates insulin resistance, do not appear to be essential in the pathogenesis of insulin 
resistance in the vast majority of diabetic patients [26]. 
2.1.4. Insulin Receptor Substrate Proteins 
At least 11 intracellular substrates of the IR and IGFR kinases have been identified [41]. 
Six of these belong to the family of IRS proteins, and have been termed IRS1-6 [41]. IRS 
proteins are a family of adaptor molecules, with IRS1 and IRS2 acting as central 
integrators of insulin signaling to downstream effector molecules [56]. In rodents IRS1 
and IRS2 are widely distributed, whereas IRS3 is largely limited to the adipocytes and 
brain (it is probably not expressed in humans), and IRS4 is expressed primarily in 
embryonic tissues or cell lines [41, 43, 57]. The role of IRS4 in the metabolic effects of 
insulin is probably limited because IRS4-null mice have nearly normal glucose 
homeostasis [43]. There are five IRS proteins expressed in humans: IRS1, IRS2 and  
IRS4-6 [56]. IRS5 and IRS6 seem to have limited tissue expression and function in 
signaling [41]. IRS family members vary in their tissue distribution and subcellular 
localization, and in their relative importance in different cells and tissues and therefore 
can mediate specific actions of insulin, despite their structural similarities [3, 8, 56]. 
IRS proteins are characterized by amino-terminal PH domains and  
phosphotyrosine-binding (PTB) domains that enable the binding of IRS1 to PI3K, and 
central and carboxy-terminal numerous tyrosine residues that can undergo 
phosphorylation by the insulin receptor tyrosine kinase, thereby enabling the binding to 
intracellular molecules that contain SH2 domains [3, 6, 40, 41]. The PH domain brings IRS 
proteins to the membrane in proximity to the IR [6]. The PTB domain of IRS binds to a 
phosphorylated tyrosine located in the juxtamembrane region of the IR [3, 6]. IRS 
proteins are also substrates for many serine/threonine kinases downstream of other 
signaling networks and become serine phosphorylated in response to various conditions 
such as inflammation, stress and over-nutrients [61]. Thus, IRS proteins coordinate 
signals from the insulin and IGFR tyrosine kinases with those generated by 
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proinflammatory cytokines and nutrients [62]. Tyrosine-phosphorylated IRS1 and IRS2 are 
upstream mediators of Akt activation whereas serine phosphorylation negatively 
modulates IRS1-mediated insulin signaling [19]. Degradation of IRS proteins can be a 
contributing factor in the development of insulin resistance [8]. 
Insulin induces the phosphorylation of a complex array of sites (under physiological 
conditions in time-controlled manner) that allows the fine-tuning of its signaling [6]. 
Positive regulatory sites are phosphorylated first by kinases in the insulin signaling 
pathway such as Akt and PKCζ [6]. This phosphorylation allows a correct tyrosine 
phosphorylation of IRS1 and the propagation of the insulin signal [6]. Inhibitory sites are 
phosphorylated later on by PKCζ and mTOR/S6K and decrease the tyrosine 
phosphorylation of IRS1 leading to the termination of the insulin signal [6]. Serine 
phosphorylation of the IRS proteins impairs their ability to be tyrosine phosphorylated, 
which increases their association with 14-3-3 proteins, removing them from the insulin 
signaling cascade [3]. The MAPK pathway also mediates down-regulation of IRS1 
expression induced by inflammatory cytokines [6]. Taken together, IRS protein signaling 
is highly regulated by processes including tyrosine and serine/threonine 
phosphorylation/ dephosphorylation and ubiquitination-mediated proteasomal 
degradation, which might be an important mechanism of insulin resistance during acute 
injury and infection, or chronic stress associated with aging or obesity [5, 8, 56, 61, 62]. 
These processes control the magnitude and duration of the response to insulin at the 
level of the IRS protein [56]. Chronic glucose, insulin or IGF1 exposure of various cell lines 
leads to increased serine/ threonine phosphorylation mediated proteasomal 
degradation of IRS2 induced by a mTOR-dependent down-regulation of PI3K/Akt/mTOR 
activity [56]. 
2.1.4.1. Differential Roles of IRS Proteins 
Decreased hepatic IRS1 correlates with the increased expression of genes that are 
involved in gluconeogenesis, whereas down-regulation of hepatic IRS2 results in 
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enhanced expression of genes that are involved in lipogenesis [41]. IRS1 has robust 
interaction with GRB2, leading to activation of the RAS-MAPK pathway, whereas IRS2 
interacts only weakly with GRB2, suggesting that, in this context at least, IRS1 
segregates best with mitogenic, and IRS2 with metabolic outcomes [43]. At least in 
muscle cells, IRS1 and IRS2 seem to participate differentially in the mitogenic and 
metabolic signals of events downstream of Akt, ERK and p38 MAPK [43]. IRS1 regulates 
actin remodeling, Akt1 and Akt2 phosphorylation, GLUT4 translocation and glucose 
uptake, whereas IRS2 contributes to Akt2 activation but makes a minimal contribution 
to GLUT4 or glucose uptake [43]. Conversely, ERK is primarily downstream of IRS2, 
whereas p38 MAPK is activated equally and complementarily via IRS1 and IRS2 [43]. IRS1 
seems to be the main mediator of insulin signaling in skeletal muscle, adipose tissue, 
and pancreatic β-cells [57]. IRS1 emerged from studies using cells in culture, animal 
models and human studies as the most relevant isoform regulating metabolic outcomes 
in muscle and adipose tissues, whereas in liver, IRS1 and IRS2 have complementary roles 
in insulin signaling and metabolism [43]. IRS2 is important for β-cell proliferation besides 
liver metabolism [57]. The loss of IRS1 or IRS2 has a negative effect on glucose 
homeostasis in mice, whereas the loss of IRS3 has a neutral and the loss of IRS4 only a 
slightly negative effect [3]. 
2.1.5. Insulin Resistance 
Insulin resistance is a pathological condition in which insulin becomes less effective at 
lowering blood glucose levels [24]. Essentially, inhibition of the insulin signaling 
pathway leads to insulin resistance [42]. The pancreatic islets respond to insulin 
resistance by enhancing their cell mass and insulin secretory activity which, over time, 
leads to the exhaustion of these compensatory reactions, and insulin deficiency and 
ultimately T2DM develop [24]. Insulin resistance is typically present throughout the 
progression from pre-diabetes to the later stages of T2DM [24, 42]. By contrast, the onset 
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of T2DM and its progression are largely determined by the progressive failure of β-cells 
to produce sufficient levels of insulin [24]. 
Insulin resistance is an important pathophysiological factor in the development of 
cardiovascular and liver diseases [6]. Concerning insulin resistance, it is clear that not all 
insulin-regulated processes and tissues become equally resistant to insulin [3]. Moreover, 
the hyperinsulinemia that evolves with insulin resistance may lead to increased insulin 
action in tissues or pathways that are not as resistant as those related to glucose 
metabolism [3]. Most cases of insulin resistance are due to a combination of factors 
acting to create partial resistance in some, but not necessarily all, pathways of insulin 
action [3]. The phenotype of insulin resistance depends on the exact components 
affected (the more proximal in the signaling pathway the more extensive the 
ramifications) and the exact tissues in which they are affected [3]. Candidates for insulin 
resistance genes are the IR, the IRS1 and IRS2, and the PI3K [26]. 
Insulin resistance results from a complex interplay between nutrient overload, systemic 
fatty acids excess (such as the sphingolipid ceramide (CER) and diacylglycerol (DAG)), 
inflammation of the adipose tissue, endoplasmic reticulum and oxidative stresses and 
hypoxia of the adipose tissue [6]. Partial loss of mitochondrial activity (responsible for 
fatty acid oxidation and respiration) goes hand in hand with the development of insulin 
resistance [4]. Accumulation of intracellular lipid metabolites, such as CER and DAG, was 
found to activate PKC and lead to dephosphorylation of Akt, thus interfering directly 
with the insulin signaling cascade, and so inducing hepatic insulin resistance, which is 
generally manifested by hyperglycemia [63]. Nitric oxide has been implicated in 
mediating insulin resistance [8]. A possible mechanism for this effects is demonstrated 
by the induction of IRS1 degradation by cytokine-inducible nitric oxide synthases and 
nitric oxide in cultured muscle cells [8]. The ubiquitin proteasome system has a role in 
down-regulating IRS proteins and thereby contributing to the two main defects in 
diabetes, insulin resistance and impaired insulin secretion [8]. 
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Insulin resistance can also be produced by the interaction of inhibitory proteins with 
components of the insulin signaling cascade, further increases in the activity or amount 
of the enzymes that normally reverse insulin action, including the phosphotyrosine 
phosphatases that catalyze the dephosphorylation of tyrosine-phosphorylated proteins 
and are important negative regulators of tyrosine kinase receptor-mediated signaling, 
e.g., PTP1B or leukocyte antigen-related protein tyrosine phosphatase (LAR-PTP), and 
the PIP3 phosphatases, e.g., PTEN and SHIP, can lead to insulin resistance  
(figure 3) [3, 19, 26]. PTP1B is a major negative regulator of insulin and leptin  
sensitivity; it interacts directly with the IR and dephosphorylates it and the leptin 
receptor-associated Janus kinase 2 (JAK2), thereby reducing their activity [19, 41]. High 
glucose enhances PTP1B transcription in human hepatocytes [19]. IR and IGFR are 
substrates for PTP1B [19]. In humans, PTP1B polymorphisms are associated with insulin 
resistance, obesity, and other characteristics of metabolic syndrome in some 
populations [19]. Serine phosphorylation of IRS1 in insulin resistant states is associated 
with decreased insulin-stimulated tyrosine phosphorylation of IRS1 resulting in the 
decreased ability of this protein to mediate signaling [8]. Indeed, reduced tyrosine 
phosphorylation of both IR and IRS proteins has been associated with the development 
of insulin resistance using in vitro and in vivo models [64].  
Other proteins, such as suppressor of cytokine signalling-1 (SOCS1) and SOCS3,  
growth-factor-receptor bound protein 10 (Grb10) and plasma-cell-membrane 
glycoprotein-1 (PC1) down-regulate IR function by sterically blocking its interaction with 
the IRS proteins, or by modifying its kinase activity [41]. The SOCS proteins, induced by 
inflammatory cytokines, have been shown to be up-regulated in states of insulin 
resistance, such as obesity, and therefore might contribute to the pathophysiology of 
diabetes [8, 41]. Moreover, over-expression of these proteins stimulates degradation of 
IRS1 and IRS2 in cultured cells and in mouse liver [8]. The IR is also down-regulated at the 
protein level by ligand-stimulated internalization and degradation, which is a common 
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feature of most insulin-resistant, hyperinsulinemic states, including obesity and 
T2DM [41].  
In obesity and diabetes, chronically activated mTORC1/S6K signaling promotes insulin 
resistance by a negative feedback mechanism involving serine phosphorylation and 
degradation of IRS1 as well as inhibition of IRS1 transcription [6]. Metabolic and 
inflammatory stresses derange the time controlled physiological feedback mechanism of 
IRS serine phosphorylation [6]. Several kinases including inhibitory-κ B kinase β (IKKβ),  
c-Jun amino-terminal kinases (JNK), ERK, mTOR, and p70S6 kinase are activated by these 
stresses that induce insulin resistance and phosphorylate IRS proteins on several serine 
residues in an uncontrolled manner [6]. The IKKβ is the master regulator of nuclear 
factor kappa B (NF-κB) activation in response to inflammatory stimuli [6]. IKKβ is 
activated by the inducers of insulin resistance such as the inflammatory cytokines and 
FFA, and IKKβ activity and/or expression are increased in obese patients [6]. In various 
insulin target cells, the inhibition of IKKβ activity prevents the deleterious effects of 
tumor necrosis factor alpha (TNFα) or fatty acids on insulin signaling [6]. The NF-κB and 
JNK pathways are activated in multiple tissues in obesity and T2DM, and have central 
roles in promoting tissue inflammation induced by overnutrition [6, 24]. Activation of 
IKKβ/NF-κB pathway in the liver and in myeloid cells, which can be inhibited by Aspirin® 
and salicylate, is a core mechanism that connects metabolic inflammation and insulin 
resistance, both in peripheral tissues and in the central nervous system [6]. 
2.1.5.1. Manifestation of Insulin Resistance in Different Tissues 
Insulin resistance is associated with a spectrum of renal diseases (from nephrotic 
syndrome, mild renal dysfunction and focal segmental glomerulosclerosis in obesity to 
diabetic nephropathy) and also with significant changes in glucose and lipid 
homeostasis [64]. FFA are elevated in insulin-resistant states and are thought to play a 
critical role in the progression to T2DM [64]. Palmitate is the predominant circulating 
SFA, and elevated plasma FFA have been identified in both adult and childhood obesity 
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and are strongly implicated in the causation of insulin resistance [64]. Furthermore, high 
levels of palmitate correlate with increased CER production, and both endogenous and 
exogenous CER have been associated with the development of cellular insulin 
resistance, i.e. in podocytes and in skeletal muscles [64]. 
Studies in humans and in rodents have demonstrated that the mechanisms leading to 
an excess accumulation of hepatic triglycerides are mainly linked to increased delivery 
of FFA from peripheral adipose tissue to the liver and enhanced de novo lipid synthesis 
via the lipogenic pathway in the liver itself, while lipid disposal via β-oxidation and very 
low density lipoprotein (VLDL) export are only moderately affected [65]. Basal 
hyperinsulinemia and chronic high fat availability have also been shown to promote a 
condition in which incomplete fatty acid oxidation and accumulation of lipotoxic short 
chain fatty acids occur in peripheral tissues, ultimately leading to a complete loss of 
their insulin sensitivity [66]. An imbalance between fatty acid uptake and oxidation is 
believed to be responsible for accumulation of lipids (such as long chain acyl CoA, DAG, 
triacylglycerol, and CER), and is thought to be a major cause of insulin resistance in 
obesity and diabetes, due to lipid accumulation and inhibition of one or more steps in 
the insulin signaling cascade [67]. When fatty acid β-oxidation is increased in heart 
muscle, glucose oxidation is consequently decreased, a phenomenon that is termed the 
“Randle Cycle” and is proposed to contribute to insulin resistance in oxidative muscles 
(type 1 skeletal muscle and heart muscle) in general [67]. It is suggested that, besides 
increased fatty acid uptake, increased fatty acid β-oxidation also contributes to insulin 
resistance in the heart and skeletal muscle [67].  
Muscle insulin resistance associated with obesity and T2DM in humans is associated with 
a dramatic decrease in signaling through IRS1 and PI3K, while signaling through MAPK 
is maintained [3]. Adipocytes from obese individuals show a decrease in IR tyrosine 
kinase activity and IRS1-associated PI3K activity; however, IRS2-associated PI3K activity is 
maintained at normal levels [3]. In liver, on the other hand, there is essentially no 
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change in the number of IR per hepatocyte, IR kinase activity, and the ability of insulin 
to inhibit glycogenolysis [3].  
In C57BL/6J mice weaned on to a lard-based high-fat diet (45% energy from fat), whole-
body insulin resistance was detected after 3 and 8 weeks on the high-fat diet and was 
entirely due to an inability of insulin to suppress endogenous glucose production from 
the liver, while muscle and adipose tissue and all other peripheral tissues retained full 
insulin sensitivity [68]. Further, hepatic insulin resistance was associated with 
accumulation of short- to medium-chain and depletion of long-chain fatty 
acylcarnitines [68]. More recent studies demonstrate that increasing lipid oxidation in 
the liver prevents hepatic steatosis and insulin resistance [12]. In a study, two weeks of 
high-fat feeding in male, 12–16 weeks old, C57Bl/6 mice resulted in hepatic insulin 
resistance in the presence of hepatic steatosis; the former reflected by decreased 
inhibition of hepatic glucose production without affecting muscle specific insulin 
sensitivity [69]. 
Hepatic insulin resistance can be defined as the failure of insulin to adequately suppress 
hepatic glucose production, further it leads to impaired glycogen synthesis and synthesis 
of inflammatory proteins; but the lipogenic actions of insulin are not compromised in 
insulin-resistant states [23, 33]. Hepatic insulin resistance is critical in triggering the 
progression to uncontrolled T2DM [26]. The failure of insulin to suppress hepatic glucose 
production is a key feature of insulin resistance and is a major factor contributing to 
hyperglycemia in diabetic states [8, 33]. Insulin exerts this effect by suppressing 
transcriptional activation of genes encoding enzymes in the gluconeogenic pathway [8]. 
Increased release of cortisol by visceral adipose tissue could play a role in hepatic insulin 
resistance by maintaining the expression of key enzymes of gluconeogenesis and, thus, 
hepatic glucose production, at a high level [65]. Chronic hyperglycemia also activates 
transcription of the insulin gene, resulting in de novo synthesis of insulin [8]. IRS2 and its 
downstream targets PI3K, Akt and FOXO1 are implicated as critical nodes of insulin 
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action in liver which suggests that impaired IRS2-mediated signaling may represent a 
major component of hepatic insulin resistance [19]. Besides insulin resistance can be 
promoted by excessive hepatic accumulation of fat [23]. The reduced adiponectin 
production by adipocytes is another potential factor in the development of insulin 
resistance [5].  
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2.2. Cytohesins 
Cytohesins are a subfamily of small guanine nucleotide exchange factors (GEF) (in 
contrast to the large ARF-GEF of about 200 kDa, which also contain a Sec7 domain), that 
catalyze the activation of adenosine diphosphate ribosylation factors (ARF) through 
replacement of GDP with GTP; they are referred to as the Sec7 family, based on 
homology of their catalytic domains to the yeast ARF GEF, sec7p [70-74]. Cytohesins are 
resistant to the inhibitor brefeldin A, a fungal macrocyclic lactone, and have a molecular 
weight around 47 kDa [55, 71-73, 75-78]. All vertebrates express four cytohesin isoforms, 
cytohesin 1, cytohesin 2, cytohesin 3, and cytohesin 4, while only one isoform (named 
steppke) is present in Drosophila melanogaster (table 1) [71].  
Name Alternative titles Accession No. 
Cytohesin 1 Pleckstrin homology, Sec7, and coiled-coil domains protein 1 (PSCD1); SEC7; D17S811E NM_011180 
Cytohesin 2 
Pleckstrin homology, Sec7, and coiled-coil domains 




Pleckstrin homology, Sec7, and coiled-coil domains 
protein 3 (PSCD3); ARF nucleotide-binding site opener 3 
(ARNO3); General receptor of phosphoinositides 1 
(GRP1) 
NM_011182 
Cytohesin 4 Pleckstrin homology, Sec7, and coiled-coil domains protein 4 (PSCD4); CYT4; DJ63G5.1 NM_028195 
Table 1. Names of the cytohesin family members [79, 80]. 
While both cytohesin 2 and cytohesin 3 appear to be ubiquitously expressed, 
cytohesin 1 and cytohesin 4 are primarily found in leukocytes [71]. Human cytohesins 
exhibit at least 80% similarity in a pair wise comparison of their amino acid sequences 
and share a common domain organization [81]. Inactive cytohesins are located in the 
cytosol [76]. In cells, the cytohesins are distributed primarily to the cell periphery, and 
can be acutely recruited to the plasma membrane in response to PI3K signaling and 
phosphoinositides (not limited to products of PI3K) stimulate cytohesin GEF  
activity [71, 78]. Cytohesins participate in the regulation of diverse processes such as 
cytoskeletal organization, integrin activation or insulin signaling [55, 75, 82, 83]. 
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Cytohesin 1 and 2 also interact with the cytoplasmic sequence of the LFA-1 β2 chain, 
CD18, which reflects a role of these proteins in signal complex assembly with the 
cytoplasmic tail of β2 integrins [82]. This interaction results in an increased avidity of 
integrin substrate binding, and thereby cytohesins mediate β2 integrin-dependent 
adhesion of T-cells [84]. The GEF activity of cytohesin 1 appears to play a minor role, if 
any, in this activity, and T-cell adhesion is only weakly inhibited by SecinH3 [84]. In a 
study, cytohesins were identified as ErbB receptor activators that enhance receptor 
activation by direct interaction with the cytoplasmic domain of the receptor [85]. In this, 
cytohesins do neither influence receptor dimerisation nor require receptor 
autophosphorylation for binding, but function as conformational activators of receptor 
dimers [85]. It is also indicated that the cytohesin-mediated activation of ErbB receptors 
does not involve the ARF proteins, nor does it require the GEF function of the Sec7 
domain [85]. 
Beside the conserved, central catalytic, Sec7 domain, responsible for GEF activity, 
cytohesins contain a carboxy-terminal PH domain, mediating recruitment to the plasma 
membrane by binding to phosphatidylinositides, an amino-terminal coiled-coil (CC) 
region (containing heptad repeats) for protein-protein interactions and  
homo-dimerisation, a polybasic (PB) motif, a Sec7 and PH-linker (SP) domain, and PH 
and PB-linker domain (figure 4) [55, 70, 76, 78, 81, 86].  
 
Figure 4. Schematic depiction of cytohesin domains. i) CC domain in green; ii) Sec7 domain 
in yellow; iii) Sec7/PH-linker (SP) in orange; iv) PH domain in red; v) PH/PB-linker in lilac; 
vi) PB-domain in blue. N amino terminus, C carboxy terminus. Adapted from [71, 81, 86]. 
The Sec7 domain consists of an elongated cylinder comprised of 10 transverse  
α-helices, separated into two sub domains by a deep, solvent-exposed hydrophobic 
groove [71]. A key feature of the catalytic mechanism is the presence of an invariant 
glutamate residue at the tip of a hydrophilic loop between helix 6 and 7, referred to as 
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‘glutamic finger’ [71]. In crystal structures of the Sec7 domain/ARF complex, this 
glutamate residue is inserted into the nucleotide-binding fold where it competes 
electrostatically with the β-phosphate of the bound nucleotide [71]. The Sec7 domain is 
proposed to act as a dual catalyst, facilitating both nucleotide release and 
conformational switching on ARF proteins [87]. Cytohesin 1 to 3 are strongly auto-
inhibited through an intramolecular mechanism that requires the PB motif [86]. Further, 
a high-resolution crystal structure of cytohesin 3 (lacking the CC domain) revealed the 
regulatory importance of a structure connecting the Sec7 and PH-domains which, 
together with the PB domain, is involved in cytohesin auto-inhibition [81].  
Several proteins have been identified that interact with the amino-terminal CC domain 
of cytohesins, including cytohesin interacting protein (Cytip, also known as CASP and 
Cybr), the related protein tamalin (also known as Grp1-associated scaffold protein, 
GRASP), and interacting protein for cytohesin exchange factors (IPCEF) [71]. These 
proteins function as adaptors, linking the cytohesins to other proteins and may provide 
a phosphoinositide independent mechanism for coupling receptor signaling to ARF 
activation [71]. For instance, tamalin has been shown to bind to metabotropic 
glutamate receptors and the neurotrophin receptor TrkC (tropomyosin-receptor-kinase 
C) via an amino-terminal PDZ (PSD-95, Discs-large, ZO-I) domain, and associates with 
multiple cytohesins via its carboxyl terminus [71].  
2.2.1.1. Cytohesin Isoforms 
The cytohesin 1 gene appears to have an extra exon of only 3 base pairs (GAG) that 
results in the insertion of a single glycine in the variable loop between the first and 
second β-sheet of the PH domain [78]. This seems to be the case for the whole family 
since the existence of two splice variants for each cytohesin has been shown [76]. In 
human brain, the mRNA for cytohesin 1 and 2 were 80–90% GAG-positive, whereas only  
20–30% of cytohesin 3 mRNA contained the GAG exon [78]. There were no major 
differences between fetal and adult human brains in percentages of the two isoforms 
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of cytohesin 2 or 3 [78]. Cytohesins, regardless of their splice isoform, can be activated 
and recruited to the plasma membrane independently of PIP3 by ARF-like GTPase 4 
(Arl4) and phosphatidylinositol-4,5-bisphosphate (PIP2) or in a PIP3-dependent manner 
(figure 3), depending on the two splice variants [71, 76]. Both variants bind PIP2, but 
only the diglycine form binds PIP3 with high affinity [76]. However, the triglycine form 
has only micro molar affinity for both PIP3 and PIP2, affinities that are insufficient to 
confer membrane recruitment, raising the question of how the triglycine forms of 
cytohesins are regulated [76]. Although PIP3 is only generated in response to external 
signals, PIP2 is constitutively present at the plasma membrane, and thus this dual 
interaction may ensure that the recruitment of cytohesin 2 by the Arl4 family is tightly 
restricted to this location [76]. The PH domain of cytohesins is necessary and sufficient 
for relocation to the plasma membrane in response to Arl4a-d, indicating that the Arl4 
family can control the localization of all four cytohesins [76]. The recruitment of 
diglycine cytohesin 2 to the plasma membrane by PIP3 has been shown to cause the 
accumulation of ARF6 on the same membrane [76]. It was found that ARF6 could also be 
recruited to the plasma membrane when cytohesin 2 was co-expressed with Arl4c, 
confirming that the cytohesin 2 recruited by an Arl4 and PIP2 was active rather than 
inhibited by the interaction with Arl4 [76]. This indicates that cytohesin 2 recruited to 
the plasma membrane by Arl4 is able to relocate ARF6 via GTP exchange [76].  
2.2.1.2. ARF 
ARF are a family of small, approximately 20 kDa heavy, ubiquitously expressed RAS-like 
GTPases that are central to many vesicular transport processes in eukaryotic  
cells [73, 77, 81, 88]. These proteins function as molecular switches and regulate a variety 
of cell biological events within both endocytotic and exocytotic trafficking 
pathways [81]. The ARF-family consists of six members that are categorized into three 
classes: class I (ARF1, ARF2, ARF3), class II (ARF4, ARF5) and class III, which is represented 
by ARF6 [77, 81, 88]. Insulinotropic concentration of glucose stimulates ARF6 
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activation [89]. The activation of ARF (“on”-state in the GTP-bound form) is driven by 
GEF, while their deactivation (“off”-state in the GDP-bound form) is catalyzed by 
GTPase-activating proteins (GAP) [81, 88]. Since GDP/GTP-exchange is coupled to  
high-affinity membrane binding of ARF, ARF-GEF (i.e. cytohesins) are also responsible 
for recruiting ARF to specific membrane domains (figure 3) and are, thus, capable of 
regulating ARF activity in a spatial manner [81]. The cytohesin family of ARF-GEF, like 
ARF themselves, cycle between inactive and active conformations, resulting in even 
more tight regulation of ARF activation [81]. 
2.2.2. Cytohesin 1 
Cytohesin 1 was initially characterized as an activator of β2-integrin-mediated adhesion 
(hence the name cytohesin) [71]. Localized at the plasma membrane, its substrates are 
ARF1 and ARF domain protein 1 (ARD1) while interaction protein for cytohesin exchange 
factors-1 (IPCEF1), β2 integrin, adenosine diphosphate ribosylation factor-related protein 
(ARP), Arl4, and CASP constitute binding partners [71, 88]. Cytohesin 1 is predominantly 
expressed in hematopoietic cells, where it binds specifically to the cytoplasmic tail of the 
integrin β2 integrin subunit CD18 and regulates adhesion (i.e. regulating LFA-1 
activation leading to adhesion of T cells to ICAM-1 (intercellular adhesion molecule 1) 
which is presented on endothelial cell surfaces) and migration of leukocytes, 
through mechanisms that require both catalytic and non-catalytic functions of the 
protein [71, 72, 82, 90-93]. The common denominator of both functions is the positioning 
of the protein upstream of the GTPase RhoA activation [92]. The exchange activity of 
cytohesin 1 is not required for integrin activation, but it is required for spreading, 
suggesting that cytohesin 1 plays different roles in inside-out versus outside-in T cell 
integrin signaling [90, 91]. A study suggested involvement of cytohesin 1 in the 
regulation of the functional responses of human polymorphonuclear neutrophils (PMN) 
and linked these events, in part at least, to the activation of ARF6 [94]. Cytohesin 1 is a 
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key regulatory molecule in the mediation of inflammatory processes and plays a role in 
synaptic transmission [88, 95].  
2.2.3. Cytohesin 2 
Cytohesin 2 is implicated in the remodeling of the actin cytoskeleton, G-protein receptor 
desensitization, and activation of calcium-regulated exocytosis [71, 88]. Also, it has been 
shown to promote the migration of epithelial cells and the outgrowth and branching of 
neurites through a mechanism that requires its catalytic activity [71, 88]. In both 
contexts, activation of ARF6 by cytohesin 2 leads to the downstream activation of the 
Rho family GTPase Rac1, which is necessary for both cell migration and neurite 
outgrowth [71]. It has been reported that cytohesin 2 is part of a GTPase signaling 
cascade in which integrin-mediated activation of R-RAS leads to recruitment of 
cytohesin 2 through an interaction with the R-RAS effector protein RLIP76/RalBP1 [71]. 
The resulting activation of ARF6 again leads to downstream activation of Rac1 and the 
resulting extension of lamellipodia [71]. Pharmacological or molecular biological 
inhibition of cytohesin 2/Arf6 inhibits glucose-induced activation of Cdc42 and Rac1 [89]. 
Glucose promotes association between cytohesin 2 and Arf6 and induces Arf6 activation 
which is inhibited by SecinH3 or siRNA-cytohesin 2, suggesting a critical involvement of 
cytohesin 2/Arf6 in insulin secretion in the pancreas [89]. Involvement in vascular 
endothelial growth factor signaling in endothelial cells was recently demonstrated for 
cytohesin 2 [96]. 
Cytohesin 2 has also been implicated in several distinct aspects of vesicular transport 
including the docking and fusion of secretory granules in adrenal chromaffin and 
neuroendocrine cells, the endocytosis/desensitization of a subset of G-protein-coupled 
receptors through an interaction with β-arrestins, and the regulation of post-endocytic 
trafficking via an interaction with the vacuolar adenosine triphosphatase  
(V-ATPase) [71]. It has been shown that the V-ATPase functions as an endosomal  
pH-sensor that recruits ARF6 and cytohesin 2 to the endosomal membrane and provides 
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a regulatory link between intra-endosomal acidification and protein trafficking in the 
endosomal respectively lysosomal protein degradative pathways [71, 81]. Further was 
discovered that cytohesin 2 binds directly to all a-subunit isoforms of the V-ATPase, 
while ARF6 interacts with the c-subunit isoform, and that both interactions require an 
acidic pH in the endosomal lumen [71, 81, 97]. Its other binding partners are GRASP, 
IPCEF1, A2A adenosine receptor, Arl4, ARF6, and CASP [71, 88]. ARF1-3 and ARF6 function 
as substrates for cytohesin 2 [71, 88]. It is localized at the plasma membrane and the 
endosomal membrane [71, 88]. The ARF-GEF activity of cytohesin 2 is regulated by 
serine-phosphorylation of its PB domain by protein kinase C (PKC) [81]. 
2.2.4. Cytohesin 3 
Cytohesin 3 plays a role in growth-factor signaling (i.e. insulin, epidermal growth factor, 
nerve growth factor) [88]. It is an essential component of the PI3K pathway in insulin 
signal transduction of Drosophila, mouse, and human cells and is localized at the plasma 
membrane [55, 71, 72, 75]. While ARF1 acts as its substrate, ARF6 is its binding partner as 
well [71, 88]. Other binding partners are IPCEF1, GRASP, GRP1 signaling partner-1 (GRSP1), 
thyroid hormone receptor, Arl4, and CASP [71, 88]. 
The PH domain of cytohesin 3 exhibits selectivity for PIP3 over phosphatidylinositol-3,4-
bisphosphate and PIP2 but it has significant affinity for phosphatidylinositol-3,4-
bisphosphate-containing vesicles [98, 99]. The PH domain of cytohesin 3 binds to PIP3 
and, to a much lesser extent, to phosphatidylinositol-3,4-bisphosphate [99]. In contrast 
to the PH domain of cytohesin 3, the PH domain of cytohesin 2, which is known to 
specifically bind PIP3, showed two-fold higher affinity for phosphatidylinositol-3,4-
bisphosphate vesicles than for PIP3 vesicles [98]. The PH domain of the two glycine 
isoform of cytohesin 2 has modest selectivity for phosphatidylinositol-3,4-bisphosphate 
over PIP3 and a lower affinity to PIP3-containing vesicles than the PH domain of 
cytohesin 3 [98]. Measurements showed that the PH domain of Akt to have a 1.7-fold 
preference for phosphatidylinositol-3,4-bisphosphate over PIP3 [98]. The PH domain of 
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cytohesin 3 translocates faster to the plasma membrane than the PH domain of 
cytohesin 2 and both show similar monolayer penetration behaviors but the PH domain 
of cytohesin 2 dissociates from model and cellular membranes more slowly than the PH 
domain of cytohesin 3 [98].  
2.2.5. Cytohesin 4 
The amino acid sequence of the Sec7 domain of cytohesin 4 is 77% identical to those of 
cytohesins 1, 2, and 3, which are more than 86% identical to each other [78]. Cytohesin 4 
mRNA is present predominantly in peripheral blood leukocytes and not in bone marrow 
cells [78]. Cytohesin 4 mRNA is abundant in both CD31/CD41 (helper) and CD31/CD81 
(cytotoxic) T-cells [78]. Most CD33+ cells (largely monocytes), 80% of CD2+ cells (NK, 
helper, and cytotoxic T-cells), and 10–20% of CD19+ cells (B-cells) also contain 
cytohesin 4 mRNA, whereas CD15+ cells (mostly granulocytes) do not [78]. It appears that 
cytohesin 4 is expressed in the more mature cells of T-cell and myelomonocytic lineages 
(and some B-cells) [78]. Cytohesin-4 exhibits GEF activity in vitro with both ARF1 and 
ARF5 but is inactive with ARF6 [78]. Known binding partners of cytohesin 4 are IPCEF1 
and CASP [88]. 
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2.3. Validity of the Diet-Induced Obesity Model in Animals 
Data from a study in 1988 showed that exposure to a high-fat, high-simple-
carbohydrate, low-fiber diet produced obesity in mice, and suggested that the C57BL/6J 
mouse carries a genetic predisposition to develop non-insulin-dependent (type 2) 
diabetes [100]. A deletion in the genetic locus of nicotinamide nucleotide 
transhydrogenase only observed in C57BL/6J mice was shown to account for their 
glucose insensitivity and reduced insulin secretion [101, 102]. Male C57BL/6J mice 
developed fasting hyperglycemia and hyperinsulinemia after 6 weeks on the Surwit Diet 
(which was used in my setup) [100, 103]. High-fat feeding will readily induce obesity and 
diabetes in C57bl/6 mice, which are frequently used as animal models of  
overfeeding [8, 104]. Post weaning consumption of diets rich in SFA results in the 
progressive development of insulin resistance, leptin resistance, and obesity in C57BL/6J 
mice [66]. Independent of the precise nature of the diet, DIO in rodents results in many 
of the same changes as seen in human obesity, including the development of central 
and peripheral leptin and insulin resistance, and in the altered expression of adipokines 
(adiponectin and resistin) which are known to contribute to the regulation of 
peripheral insulin sensitivity [10]. DIO was shown to be associated with a reduced 
pancreatic abundance of enzymes involved in clearance of reactive oxygen species, 
providing a potential mechanism for the deterioration of pancreatic function seen in 
the later stages of T2DM, with adipocyte hypertrophy and the induction of hepatic 
steatosis and hepatic insulin resistance, which again resembles the human obese state 
(figure 1) [10].  
Oxidative stress has emerged as an important factor in the pathogenesis of obesity and 
T2DM [33]. High-fat feeding in rats has been shown to increase hepatic oxidative stress, 
and reactive oxygen species synthesis has been proposed as an initial event that 
precedes the onset of insulin resistance in mice fed a high-fat diet [33]. 
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DIO can not only be observed in rodents but also in primates: In more than 50% of 
nonhuman primates obesity develops over years as they age [5]. Nearly half of these 
obese animals subsequently develop diabetes, as a greater BMI correlates with greater 
insulin secretion [5]. Once the animals gain weight, impaired glucose removal from the 
blood stream and increased insulin resistance are detectable [5]. The hyperinsulinemia, 
in turn, leads to an increase of hepatic VLDL triglyceride synthesis and secretion, 
increased plasminogen activator inhibitor-1 synthesis, increased sympathetic nervous 
system activity, and increased renal sodium reabsorption [5].  
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2.4. Aim of the Dissertation 
Cytohesins are important regulators of hepatic insulin signaling in vivo at the level 
between IR and IRS [71]. Specific inhibition of cytohesin 3, a protein involved in the 
intracellular part of the insulin signaling pathway, by SecinH3, a small organic inhibitor 
(a 1-, 2-, 4-substituted triazole), leads to hepatic insulin resistance [75, 84]. SecinH3 is 
known to inhibit nucleotide exchange, insulin signaling, and to a part cell adhesion [84]. 
This dissertation examines effects of high-fat diet feeding (which lead to impaired 
glucose tolerance) on cytohesin 2 and cytohesin 3 mRNA steady-state expression levels 
and cytohesin 3 protein expression levels in murine liver using quantitative real-time 
PCR (qRT-PCR) and Western blot analysis. 
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3. Methods 
3.0. Animals and Dietary Treatments  
In this dissertation I analyzed livers of mice derived from a study in which effects of 
high-fat diet on the cardiovascular system was analyzed in a mouse model. Parts of the 
results were published in the manuscript with the title “Fat intake modifies vascular 
responsiveness and receptor expression of vasoconstrictors: Implications for diet-induced 
obesity” by Mundy et alii [105]. These data indicated that a higher fat quota in chow 
leads to impaired glucose tolerance [105].  
Diet C HF VHF 
Protein 22.4 17 16.4 
Carbohydrate 65.4 43 25.5 
Fat 12.3 41 58 
Table 2. Major macronutrient constituents of diets given in percent of kcal. Taken from [105].  
For that study healthy male mice (C57BL/6, Charles River, Sulzfeld Germany) 
were housed in the institutional animal facilities on a 12:12-hours light-dark cycle, and 
animals had free access to food and water [105]. Housing facilities and experimental 
protocols were approved by the local authorities for animal research (Kommission für 
Tierversuche des Kantons Zürich, Switzerland) and conform to the Guide for the Care 
and Use of Laboratory Animals published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996) [105]. Mice were randomly assigned to one of the 
following diets (n = 10–12 mice/group, but only for 8 mice/group cytohesin levels were 
determined): control (C, 12.3% of total kcal from fat, KLIBA NAFAG 3430, Kaiseraugst, 
Switzerland), high fat (HF, 41% of total kcal from fat, Research Diets D12079B, New 
Brunswick, NJ), and a diet containing very high amounts of fat (VHF, 58% of total kcal 
from fat, Research Diets D12331) for 15 weeks [105]. The macronutrient compositions of 
the three diets are reported in table 2. At the end of the treatment, mice were 
anesthetized (xylazine: 100 mg/kg body weight; ketamine: 23 mg/kg body weight; and 
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acepromazine: 3.0 mg/kg body weight, intraperitoneal), and exsanguinated via cardiac 
puncture [105]. 
3.1. Quantification of mRNA and Protein Expression 
3.1.1. RNA Isolation and qRT-PCR 
Murine liver tissue was snap-frozen in liquid nitrogen immediately after dissection and 
stored at −80 °C. Tissue was disrupted in Buffer RLT® (Qiagen AG, Hombrechtikon, 
Switzerland) and homogenized using a Qiagen TissueLyser (Retsch, Haan, Germany). 
Total RNA was extracted using the RNeasy® Mini Kit (Qiagen AG, Hombrechtikon, 
Switzerland). 1 μg of RNA was reverse transcribed using the Quantitect® Reverse 
Transcription Kit (Qiagen AG, Hombrechtikon, Switzerland), which includes a genomic 
DNA elimination reaction. Relative expression levels of murine genes encoding for 
cytohesin 2 and cytohesin 3 were determined by qRT-PCR using murine β2 microglobulin 
as a housekeeping gene. After analyzing preliminary results, β2 microglobulin was 
chosen over β actin as housekeeping gene, because it yielded less variation of the mean 
cycle threshold (CT) values (table 4). qRT-PCR experiments were run on a iCycler™ 
Thermal Cycler (Bio-Rad Laboratories AG, Reinach, Switzerland) with iCycler iQ™ Multi 
Color Real time PCR Detection System (Bio-Rad Laboratories AG, Reinach, Switzerland) 
using specific cDNA primers (Microsynth AG, Balgach, Switzerland). The same apparatus 
was used for all reactions. The reaction for the qRT-PCR consisted of cDNA template, 
forward and reverse primers (400nM final concentration, primer sequences are shown 
in Table 3), and iQ SYBR Green Supermix (Bio-Rad Laboratories AG, Reinach, 
Switzerland) in a total volume of 25 µl. qRT-PCR was analyzed using Bio-Rad iCycler iQ™ 
Optical System Software (version 3.1.7050), following the manual provided by the 
supplier, and Microsoft® Excel.  
In all reactions containing β2 microglobulin the CT value was set at 1900 arbitrary units 
(AU) with base line range of cycle 2 to 11. Above the threshold value the increase in 
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fluorescence, and therefore cDNA, is exponential. For cytohesin 2 reactions a threshold 
value of 1949.7 AU was used with a base line range of cycle 2 to 17. In the case of 
cytohesin 3 reactions a threshold value of 2034.9 AU was used with a base line range of 
cycle 2 to 22. All reactions were performed in duplicate; specific reactions with 
differences in cycle threshold values over 0.5 cycles were repeated in order to acquire 
consistent data. Samples from all three groups were used for each 96-well PCR plate 
setup. Every group consisted of eight samples. The validity of the obtained PCR cDNA 
products was controlled by melting curve analysis and sequencing.  
Primer Primer sequences (5’–3’) Accession No. 
For: ACCTCTACGACAGCATCC (position 898, 18bp)  
m-pscd2 Rev: CCGCTTCCAAGTCTTCAC (position 1037, 18bp)  NM_011181 
For: GGTCTTCCAGTCCACAGATAC (position 739, 21bp) 
m-pscd3 Rev: CTCGTTGATGCCTCGGTTC (position 874, 19bp)  NM_011182 
For: GGTCGCTTCAGTCGTCAG (position 33, 18bp) β2 micro-
globulin Rev: TGTTCGGCTTCCCATTCTC (position 75, 19bp) NM_009735 
Table 3. Primers used for amplification of specific cDNA fragments encoding for cytohesin 2, 
cytohesin 3 and β2 microglobulin [80]. 
3.1.2. Sequencing 
Correct primer design for m-pscd2 was controlled by sequencing of the qRT-PCR product 
by Microsynth AG. The m-pscd3 primer product could not be sequenced by Microsynth 
AG. Because Microsynth AG stated that PCR products <100 bases were often problematic 
for sequencing; incorporating these PCR products into a plasmid vector instead of 
sequencing them directly was recommended. The cytohesin primers used were chosen 
to yield approximately the same product size. Since the shorter product could not be 
sequenced, I decided to prolong it. In order to increase the length of the PCR product to 
be sequenced, the m-pscd3 primer product was inserted into a plasmid using the TOPO® 
TA Cloning® Kit for Sequencing (with pCR™4-TOPO® vector) with One Shot® TOP10 
Chemically Competent E. coli and PureLink™ Quick Plasmid Miniprep Kit (Invitrogen 
AG, Basel, Switzerland). In a first step I produced the m-pscd3 primer PCR product 
following the TOPO® TA Cloning® Kit manual. In order to incorporate the PCR product 
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into plasmids it had to be mixed with the supplied TOPO® vector, amongst others. One 
Shot® TOP10 Chemically Competent E. coli were transformed using the TOPO® Cloning 
reaction. A few colonies were cultured overnight. Using the PureLink™ Quick Plasmid 
Miniprep Kit cells were lysed, the plasmid DNA was isolated and sent to be sequenced 
by Microsynth AG (table 5). 
3.1.3. Western Blot Analysis 
From the above mentioned, at −80 °C stored, mouse liver samples about 30 mg of liver 
tissue were taken without thawing of the samples. The tissue samples were disrupted in 
RIPA lysis buffer and homogenized using a Qiagen TissueLyser (Retsch, Haan, Germany). 
Supernatant was separated from tissue detritus by centrifugation. Protein concentration 
of each sample was determined by Bradfort Protein Assay. Equal amounts of protein 
lysates were separated on an 8–16% SDS-PAGE gel and immunoblotted with anti-
cytohesin 2 antibodies (cytohesin-2 (N-20): sc-9727 1:500, Santa Cruz Biotechnology Inc., 
Heidelberg, Germany), anti-cytohesin 3 antibodies (GRP1 (N-17): sc-9730 1:500, Santa Cruz 
Biotechnology Inc., Heidelberg, Germany) and anti-p44/42 antibodies (rabbit anti 
pospho-Erk1/2 (9102) 1:1000, and rabbit anti total-Erk1/2 (9102) 1:1000, Cell Signaling, 
Danvers, MA, USA). Densitometric analysis of Western blots was performed using 
ImageJ 1.44p (Wayne Rasband, National Institutes of Health, USA). 
3.2. Calculations and Statistical Analysis 
For statistical calculations and graphs, the statistic program StatView® 5.0.1 (SAS 
Institute Inc., North Carolina, USA) was used. For comparison between two groups, the 
unpaired Student’s t-test was performed. All data are expressed as mean ± standard 
error of the mean (SEM). P values <0.05 were considered statistically significant.  
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4. Results 
4.0. Presentation of Mice Used, House Keeper Testing and 
Primer Sequences 
As indicated in the method section, a study using the mice of the present study has 
already been published. The authors showed that the mice of the HF and VHF groups 
gained significantly more weight compared to group C (17±1 g respectively 21±1 g vs. 
11±1 g) [105]. In addition, glucose clearance was significantly lowered in the HF and the 
VHF groups indicating impaired glucose tolerance [105]. 
4.0.1. House Keeper Testing 
To begin with, two house keeping primers sets, amplifying about 140 bp stretches of 
β actin and β2 microglobulin sequences respectively, were tested for stability. 
β2 microglobulin was chosen over β actin because of 45% less variation in CT values 
(table 4). 
Gene mean CT value 
β actin 19.63±0.236 (18.30; 21.10) 
β2 microglobulin 17.90±0.132 (17.25; 18.65) 
Table 4. House keeper comparison. Mean CT values ± SEM; lowest, respectively highest, 
mean CT values in brackets. n = 13 per gene. 
4.0.2. Cytohesin 2 and Cytohesin 3 Amplicon Sequencing in Murine Liver 
Verified primer product sequences for cytohesin 2 and cytohesin 3 are shown in table 5. 

















Table 5. Verified primer product sequences. 
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4.1. Effects of High-Fat Diet on mRNA Steady-State Expression 
Levels of Cytohesin 2 and Cytohesin 3 in Murine Liver 
In order to determine effects of high-fat diet feeding on the expression of cytohesins, I 
investigated mRNA expression levels of cytohesin 2 and cytohesin 3 in murine livers by 
qRT-PCR. In the control samples cytohesin 2 had a seven times higher mRNA expression 
level than cytohesin 3 (table 6). This indicates that there is seven times more cytohesin 2 
than cytohesin 3 mRNA expressed in murine liver.  
Gene C 
Cytohesin 2 532±41 
Cytohesin 3 75.4±9 
Table 6. Cytohesin 2 and cytohesin 3 mRNA steady-state expression levels. mRNA expression 
levels were measured with qRT-PCR with β2 microglobulin as a house keeper using the  
∆CT-method. n = 8 per group. Values stated in arbitrary units. Data represent means ± SEM. 
4.1.1. Effects of High-Fat Diet on mRNA Expression Levels of Cytohesin 2 
In mice fed a VHF diet cytohesin 2 mRNA steady-state expression levels in liver tissue 
were significantly increased compared to control diet fed mice (24%, P<0.05 VHF vs. C, 
figure 5). However, mice fed a HF diet showed no effect in gene expressions of 
cytohesin 2 compared to mice of group C. A significant difference in gene expression 
was shown for cytohesin 2 in mice fed a VHF diet compared to mice fed a HF diet (27%, 
P<0.05 VHF vs. HF). 
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Figure 5. Effects of dietary fat content on relative mRNA steady-state expression levels of 
cytohesin 2 in mouse liver. mRNA expression levels were measured with qRT-PCR with 
β2 microglobulin as a house keeper using the ∆CT-method. n = 8 per group. AU = arbitrary 
units. Data represent means ± SEM. * P<0.05 vs. C; †P<0.05 vs. HF. 
4.1.2. Effects of High-Fat Diet on mRNA Expression Levels of Cytohesin 3 
In livers of mice fed a VHF diet cytohesin 3 gene expression levels were significantly 
increased compared to control diet fed mice (37%, P<0.05 VHF vs. C, figure 6). However, 
mice fed a HF diet showed no effect in gene expressions of cytohesin 3 compared to the 
control group. A significant difference in gene expression was shown for cytohesin 3 in 





















Figure 6. Effects of dietary fat content on relative mRNA steady-state expression levels of 
cytohesin 3 in mouse liver. mRNA expression levels were measured with qRT-PCR with 
β2 microglobulin as a house keeper using the ∆CT-method. n = 8 per group. AU = arbitrary 
units. Data represent means ± SEM. *P<0.05 vs. C; ‡P<0.001 vs. HF. 
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4.2. Effects of High-Fat Diet on Protein Steady-State 
Expression Levels of Cytohesin 3 in Murine Liver 
In order to determine effects of high-fat diet feeding on the expression of cytohesin 3 in 
liver tissue, I investigated protein level of cytohesin 3 in murine livers by Western 
blotting and subsequent analysis of the integrated density of the blots (figure 7).  

































0.976±0.098 1.027±0.101 0.872±0.044 
 
Figure 7. Steady-state protein expression analysis of p44/42 and cytohesin 3 in mouse livers. 
A) Effects of dietary fat content on protein levels of p44/42 and cytohesin 3. Samples of blots 
used for densiometric analysis. B) Cytohesin 3 to p44/42 integrated density ratios. n = 8 per 
group. Data represent means ± SEM. 
Compared to the C group, the reference protein p44/42 yielded a non-
significant decrease in protein expression levels of less than 2% in the HF group and less 
than 4% in the VHF group (data not shown). Cytohesin 3 protein expression levels 
showed a non-significant increase of 5% in the HF group and a decrease of 11% in the 
VHF, when compared to the C group. Thus, I detected that elevated fat intake had no 
significant effect on protein expression levels of p44/42 and cytohesin 3. 
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5. Discussion 
This dissertation was prompted by the publication of an article about cytohesin 
inhibition in Nature by Hafner et alii in 2006. At the time cytohesins were being 
associated with the insulin signaling cascade.  
5.0. Cytohesins and Insulin Signaling 
I determined that cytohesin 2 mRNA expression levels were seven times higher than 
cytohesin 3 mRNA levels in male C57BL/6 mice on a normal diet. Also, I found that 
impaired glucose tolerance induced by high-fat feeding in mice was not accompanied 
by significant changes in cytohesin 2 and cytohesin 3 mRNA steady-state expression 
levels and by changes in cytohesin 3 protein expression levels in murine liver tissue. Only 
the VHF group exhibited significant increases in cytohesin 2 and cytohesin 3 mRNA 
expression levels compared with control diet fed mice. But cytohesin 3 mRNA and 
protein expression levels seemed having a different translational control, because 
increased mRNA expression levels were not accompanied by increased protein 
expression levels. A possible explanation for this could be found in the coarse sensitivity 
of the Western blot analysis in comparison to the relatively high sensitivity of qRT-PCR. 
Inhibition of cytohesin 3 by SecinH3 leads to hepatic insulin resistance [75]. Knockdown 
of either cytohesin 2 or cytohesin 3 (but not cytohesin 1), or of ARF6 (but not ARF1) also 
inhibited insulin signaling in HepG2 cells [71]. Despite that, it appears that high-fat  
diet-induced impaired glucose tolerance was not caused by cytohesin 3 expression 
inhibition in the mouse liver, at least not in a (to our setup) relevant extent. Although 
autophosphorylation of the IR itself is not affected by cytohesin inhibition, subsequent 
tyrosine phosphorylation of IRS1, the next step in the pathway, was shown to be 
significantly impaired [71]. Cytohesins appear to act at a point in the insulin signaling 
pathway that precedes the recruitment of PI3K, suggesting that their association with 
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the IR is not dependent upon local phosphoinositide synthesis [71]. Experiments have 
shown that in cells the IR is physically associated with cytohesin 2 and cytohesin 3 [42]. 
That suggests that, at least these two, cytohesins are involved at the very beginning of 
cellular insulin signaling. If cytohesins precede PI3K in the insulin pathway the very 
beginning of the cellular insulin signaling remains only partially illuminated; 
nevertheless they appear to be part of the metabolic insulin pathway.  
There are several possible mechanisms of how insulin signal transduction could be 
inhibited at the level of cytohesins: i) Cytohesin gene expression is suppressed, which 
would lead to decreased cytohesin mRNA expression levels and accordingly to low 
cytohesin protein levels. ii) Gene expression of cytohesin encodes for dysfunctional 
cytohesin mRNA and protein, respectively. iii) Given normal cytohesin mRNA expression 
levels, post-transcriptional regulation could lead to decreased cytohesin protein levels. 
iv) Cytohesin proteins are inhibited in their functions through an antagonist and/or 
have to compete for substrate. v) Cytohesin proteins are spatially inhibited through 
retention in the cytosol.  
Impaired glucose tolerance is a pre-diabetic condition which can continuously proceed 
to insulin resistance. Possibly, cytohesins contribute to hepatic insulin resistance in later 
stages or their effects in earlier stages could not be detected by our experimental setup. 
An explanation for our findings could be sought in the complexity of insulin signaling 
cascade. Insulin signaling is very complex when looking at all the involved components 
of which many come in several subtypes with different effects. Different defects or 
combination of defects may have the same phenotypic consequences. This appears to be 
the case in T2DM. Because cytohesins come in to play at or near the onset of cellular 
insulin signaling, the effects of their inhibition are phenotypically evident. One might 
argue that would be the case for any inhibition of components at the beginning of 
signal transduction. But the interesting point is not that cytohesins can cause insulin 
resistance but if this actually plays a role in the genesis of insulin resistance in vivo. In 
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light of our experiments, it appears that cytohesin inhibition is not relevantly involved 
in the pathology of impaired glucose tolerance in mice in the setup used for the present 
study.  
5.1. Mechanisms of High-Fat Diet-Induced Impaired Glucose 
Tolerance 
If involvement of cytohesin 3 in the pathogenesis of high-fat diet-induced impaired 
glucose tolerance seems irrelevant – what is relevant?  
While long chain fatty acids suppress hepatic glucose output via the hypothalamus, they 
increase hepatic glucose production through a direct effect on the liver [66]. There is 
indication that FFA, triglycerides and lipid molecules act locally in the brain to influence 
leptin transport, food intake and peripheral glucose metabolism, and as such provide 
additional mechanisms through which the chronic consumption of a high-fat diet might 
be compromising body weight and glucose homeostasis [66]. But hypothalamic 
involvement in hepatic insulin resistance is proposed to be marginal, as a study 
investigated the effects of a two-week high-fat diet in 12–16 weeks old, C57Bl/6 mice on 
mRNA expression levels in hypothalamic neuropeptides involved in regulation of food 
intake and fuel homeostasis [69]. It suggests that the hypothalamus does not play a 
major role in the primacy of hepatic insulin resistance during a high-fat diet in mice [69]. 
Further was proposed that hepatic steatosis could be either a consequence of metabolic 
alterations elsewhere in the body and/or an active player in the pathophysiology of the 
metabolic syndrome [69]. Generally accumulation of lipid in tissues not designed for 
storage is a key initial step in the progression towards insulin resistance [66, 106, 107]. 
Chronic consumption of HF diets results in an oversupply of lipids to metabolic organs 
that is temporally related to periods of rapid weight gain, and associated with 
decreased insulin sensitivity and impaired glucose homeostasis [66, 106].  
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Findings from a high-fat diet mouse study indicate that hepatic steatosis is susceptible 
to oxidative stress induced by transient hypoxia for six hours and obstructive sleep 
apnea is potentially a trigger of development of NASH [108]. 
Hypothalamic control of liver metabolism can also participate in generating a 
proinflammatory milieu, at least in the liver [36]. TNFα is able to inhibit insulin- and  
leptin-induced PI3K signaling in the hypothalamus [36]. Of note, weight loss, the single 
most important lifestyle modification to prevent T2DM in overweight individuals, is 
strongly and linearly associated with reduction in C-reactive protein levels, which are 
indicative of inflammation [15]. In rodents the hypothalamus is able to sense and 
respond to hormones, cytokines, and nutrients and modulate hepatic glucose 
production accordingly [36]. Scientific evidence indicates that hepatic insulin resistance 
is caused, in part, by a failure of hypothalamic insulin, leptin, and nutrient sensing [36]. 
Macrophage accumulation in adipose tissue (recruitment, proliferation and/or retention 
of resident macrophages) as well as macrophage differentiation are the results of 
distinct mechanisms involving adipocyte-derived products, adipokines, chemokines and 
FFA, as well as local adipose tissue hypoxia and nutrient-induced metabolic 
endotoxemia [109]. Accumulation of adipose tissue macrophages, in turn, locally affects 
adipose tissue plasticity and also exerts systemic effects by favoring the release of FFA 
into the circulation and ectopic lipid storage in non-adipose tissue [109]. It seems 
evident that chronic low-grade inflammation is an important contributor to the 
etiology of insulin resistance associated with obesity, and that adipose tissue 
macrophages may play a key role in orchestrating the tissue inflammatory 
response [109]. 
Aside from fat intake, hepatic sugar excess inflicts a metabolic burden on the 
hepatocyte that selectively increases phosphorylation of MKK7 (MAPK kinase), 
activation of JNK (MAPK) and association of JNK with IRS proteins and the scaffold 
protein JIP1 [110]. Association of JNK with IRS1 reduces tyrosine phosphorylation of IRS1 
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and, thus, insulin signaling [110]. Fructose delivery also reduces tyrosine phosphorylation 
of IRS2 [110].  
Differences observed in metabolic outcomes in C57Bl/6 mice on high-fat diets are, in 
part, generated by genetic differences among C57Bl/6 substrains which were generally 
not indicated in past studies [111]. One example shall demonstrate what is meant: 
Schreyer et aliae used C57Bl/6 mice, among others, and indicated that they replicated 
the induction of diabetes and obesity showed by Surwit et alii in such mice [104]. But 
Surwit et alii reported using C57Bl/6J and other substrains and not C57Bl/6 [100, 103, 112]. 
Additionally was shown that genetic predisposition can be more important in 
determining the degree of obesity in response to a high-fat diet than caloric 
intake [112]. 
Mice and rats on very high-fat (55–60 kcal%) diets produce a rapid deterioration (3 
weeks) in whole body insulin sensitivity that coincides with a simultaneous reduction in 
insulin-dependent glucose uptake in peripheral tissues coupled with a failure of insulin 
to suppress hepatic glucose production [66]. In contrast, consuming high-fat diets with 
45% of fat for one to five weeks resulted in loss of suppression of hepatic glucose 
production by insulin without any change in insulin-sensitive glucose uptake in 
peripheral tissue [66]. Taken together, this suggests that loss of insulin sensitivity in liver 
is responsible for the initial deterioration in whole body insulin sensitivity [66]. 
Differences in metabolic outcomes among studies seem likely to be due to amount, 
source, and saturation of dietary fat, length of exposure and age of animals upon 
introduction of test diets [66]. But ambient temperature and rearing conditions may also 
affect the progression of metabolic outcomes, as was shown for the progression of diet-
induced leptin resistance using a 45% high-fat diet in C57BL/6 mice [66]. 
Further, a study shows that short-term high-fat treatment of mice seems to worsen their 
spatial learning tasks performance through impairment of hippocampus dependent 
cognition, and provides evidence that, independently of insulin, dietary intake could 
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impair learning processes by itself [113]. This would mean that (at least some) nutrients 
are capable of influencing behavior to a degree. Moreover, it was demonstrated that 
cognitive deficits arise prior to the development of hyperglycemia or 
hyperinsulinemia [113]. Possibly, dietary impairment of learning processes could lead to 
T2DM promoting behavior.  
Taken together, several factors seem relevant and contribute to high-fat diet-induced 
impaired glucose tolerance or later stages of T2DM: Ectopic fat accumulation (especially 
in the liver) and chronic low-grade inflammation generated by adipose tissues 
macrophages appear to be central, though partially, the brain appears to be involved in 
several ways, also.  
5.2. Protein Expression Levels of Cytohesin 2 
I attempted to demonstrate the effects of high-fat diet on protein steady-state 
expression levels of cytohesin 2 in murine liver but encountered problems technical in 
nature: Western blot staining with the cytohesin 2 antibodies yielded repeatedly diffuse 
blots that did not allow a secure identification of the correct bands (data not shown). 
5.3. Fat Composition of the Diets Used 
Fat content of the fodder used for group C accounted for 85% vegetable oil (soybean 
oil) and 15% animal fat (milk fat) [114, 115]. Chow for HF diet, which is described in the 
product sheet as RD Western Diet, contained predominantly animal fat: 1.9% of total 
kcal was corn oil versus 38% milk fat [116]. Whereas VHF diet, also named after its 
designer Surwit Diet, had only vegetable oil (54% of total kcal hydrogenated coconut 
oil and 4% soybean oil) incorporated [117].  
Taking into account the different origins of fat used, the question might arise if these 
are relevant to the comparison of weight gain and glucose tolerance. But despite this 
variation in the amount and source of dietary fat, in mice all high-fat diets are 
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associated with the emergence of hyperphagia, rapid weight gain and excess body fat 
accumulation [10]. Thus, fat types used to feed the mice whose livers were used in this 
dissertation do not seem to play a significant role with respect to weight gain.  
When considering that both high-fat diets (with 17% difference in fat content) elicited 
approximately the same degree of glucose tolerance impairment, quantitative 
differential effects of animal fat and vegetable oil on glucose tolerance seem probable.  
A study using healthy Swedish adults compared rapeseed (or canola) oil diet with dairy 
fat diet and found no differences between the diets with regard to insulin sensitivity or 
fasting glucose concentrations even though clinically relevant beneficial effects on the 
serum lipid profile were observed in subjects that replaced SFA with unsaturated fats of 
rapeseed oil for 3 weeks [118]. Observational studies and dietary trials suggest that 
increased consumption of trans-fatty acids (TFA, products of partial hydrogenation of 
vegetable oils, also occurring naturally in meat and dairy products from ruminants) is 
associated with increased triglycerides, LDL cholesterol, total to HDL cholesterol ratio, 
apolipoprotein B to apolipoprotein A ratio, and cardiovascular mortality and 
morbidity [119, 120]. Further, high intake of TFA has been associated with an increased 
risk of coronary heart disease and prospective cohort studies have shown that dietary 
TFA promote abdominal obesity and weight gain [120]. There is less clear or even 
conflicting evidence from observational studies regarding the effect of TFA on systemic 
inflammation, endothelial function, insulin resistance, and T2DM [119]. In addition, the 
consumption of TFA appears to be associated with the development of insulin resistance 
and T2DM [120].  
It seems that not only the quantity and source but also the processing of fat can have an 
impact on health. Partially hydrogenated sunflower oil contains 20% TFA, whereas 
unprocessed sunflower oil contains only traces of TFA [121]. Not hydrogenated coconut 
oil contains 91% SFA; hydrogenation increases TFA and SFA contents slightly [121]. Thus, 
the VHF group had a higher intake of SFA than the HF group and a comparable intake 
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of TFA. Generally, elevated SFA intake is associated with a higher risk of insulin 
resistance, but lauric acid, a medium chain SFA, may improve total to HDL cholesterol 
ratio [122]. Lauric acid constitutes approximately 49% of total fatty acid content of 
coconuts (depending on the cultivar) and may protect against diabetes-induced 
dyslipidemia [123, 124]. That could explain the comparable degree of glucose tolerance 
impairment in both high-fat diets even though the VHF diet, despite containing no 
animal fat, appeared to contain more nocuous fatty acids than the HF diet.  
5.4. T2DM Treatment 
At first T2DM treatment should involve lifestyle interventions and administration of 
antidiabetic agents [14]. Aim is to achieve HbA1c plasma concentration below 6.5% [14]. 
In case of insufficient target glycemic control through non-insulin monotherapy a 
second oral agent or insulin is added [14]. Mechanisms of action of major antidiabetic 
agents are described shortly: 
Metformin, a biguanide, leads to a reduction in hepatic glucose production mainly 
through transient inhibition of respiratory chain complex I [125]. Further, it activates  
AMP-activated protein kinase [14, 125]. Meglitinides and sulfonylureas increase insulin 
secretion through closing of KATP channels on β-cell plasma membranes [14]. Glitazones 
activate nuclear transcription factor PPAR-γ (peroxisome proliferators-activated 
receptor) which leads to increased glucose uptake through increased insulin 
sensitivity [14, 126]. α-Glucosidase inhibitors slow intestinal carbohydrate digestion [14]. 
Activation of the GLP-1 receptor by incretins results in increased cAMP production 
leading to increased synthesis and secretion of insulin and decreased glucagon 
secretion [14, 126]. That can also be achieved by inhibition of dipeptidyl-peptidase-4, an 
enzyme responsible for degradation of endogenous incretins [14, 126]. 
No information on the involvement of cytohesins in the mechanisms of action of 
antidiabetic agents was found at the time of writing. A hypothetical antidiabetic 
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substance targeting cytohesins would have to specifically activate/increase or mimic the 
action of cytohesins. But even if the action of cytohesins in the insulin signaling 
pathway could be enhanced, the practical value might be limited. Because of the 
complexity of the insulin signaling cascade, cytohesin’s involvement at the intra cellular 
beginning of this pathway, and the high probability of interference with insulin 
signaling at later stages of the cascade, an antidiabetic agent centering on the action of 
cytohesins does not seem likely to be developed. So far cytohesin research has yielded 
no clinical implications for treatment of T2DM. 
5.4.1. Diet Recommendations 
Excess body weight is the most important modifiable risk factor for the development of 
diabetes [15]. There is also an indication that lean, physically active subjects can adjust 
to the postprandial glucose challenge following a high-glycemic-index meal by 
increasing insulin sensitivity, while obese, inactive subjects must increase their insulin 
secretion in order to re-establish glucose homeostasis [15].  
Unfavorable effects of a high animal fat and protein diet, low on carbohydrates, were 
demonstrated in a cohort of male health professionals, where this diet was positively 
associated with the risk of T2DM [127]. This association was mainly due to intake of red 
and processed meat [127]. Conversely, a score representing a diet low in carbohydrate 
and high in vegetable protein and fat was not significantly associated with T2DM [127]. 
Interestingly, in a cohort of American adult men studied longitudinally for 7 years, it 
was observed that intakes of total fat and saturated fat were higher, with higher intake 
of animal protein and lower at higher levels of vegetable protein intake [128]. Further, 
animal protein intake was positively related to and vegetable protein intake was 
inversely associated with body mass and overweight/obesity, independent of other 
dietary macronutrients [128]. Thus animal and vegetable protein play different roles in 
obesity development, suggesting that replacement of animal protein with vegetable 
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protein in the diet may offer promise in future interventions aimed at 
prevention/control of overweight and obesity [128].  
Fat quality and quantity are not the only factors influencing weight gain: Long-term 
supplementation (45 weeks) of a high-fat Western-style diet with soluble highly 
fermentable guar fiber resulted in an obese phenotype in C57BL/6J mice [129]. In 
contrast, supplementing the same diet with moderately fermentable insoluble cereal 
fiber prevented a high-fat diet-induced obese phenotype in these animals [129]. 
Although dietary energy intake was comparable, weight gain and estimates of insulin 
resistance were significantly different between groups [129]. 
After four weeks of diet intervention in male C57BL/6J mice, weight loss with normal fat 
diet (12.7% of kcal from fat), but not with high-fat diet (42.0% of kcal from fat) 
restriction, markedly alleviated hepatic steatosis and inflammation as assessed by 
hepatic triglyceride and chemokine and CD11c+ expression [7]. Normal fat diet-induced 
weight loss normalized adiponectin expression in adipose tissue and tended to 
attenuate adipose tissue expression of chemokines and CD11c+, whereas high-fat diet 
restriction-induced weight loss significantly attenuated adipose tissue expression of 
chemokines and CD11c+ and tended to increase adipose tissue adiponectin [7]. 
Improvements in glucose tolerance and insulin resistance were not significantly 
different between the diets in the short observation period, but the effects of a long-
term weight loss on normal fat diet are expected to be more beneficial considering its 
ability to alleviate hepatic inflammation and steatosis [7].  
Taken together, foods rich in SFA and simple sugars (as is the case for both, HF and VHF, 
diets) are clearly deleterious for obesity and diabetes, and the best replacements are 
MUFA and fiber-rich carbohydrate foods [15]. Or differently phrased, replacing fats from 
red meats and butter with non-hydrogenated vegetable oils, margarines, nuts and seeds 
rich in MUFA and/or PUFA should be encouraged to improve insulin sensitivity, reduce 
diabetes risk, and lower cardiovascular risk by reducing the serum LDL/HDL ratio and 
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triacylglycerols [17]. This is reflected in the macronutrient recommendations for diabetes 
management where SFA intake should be below 7% of total calories [14].  
5.5. Conclusion 
Today, cytohesin research is concerned mainly with cancer and immunology 
research [130]. A search for cytohesin on PubMed.gov yielded 187 search results 
compared to 18 hits for cytohesin and insulin [130, 131]. Only about a third of the latter 
addressed insulin signaling in depth and most of these were published in 2006 and 
2007, when this dissertation started. Thus today, it appears, there is little scientific 
attention directed at the details of cytohesins participation in insulin signaling. 
This study could not demonstrate any impact of diet-induced obesity (leading to 
impaired glucose tolerance) on steady-state expression levels of cytohesin 2 and 
cytohesin 3 mRNA in murine liver. If cytohesins are involved in the pathogenesis of 
impaired glucose tolerance and/or T2DM in vivo, they seem to play a subordinate role. 
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8. Appendix 
Preparation of RIPA Buffer: The following amounts of the constituents listed below 
were mixed in a beaker and filled up to a volume of 100 ml with distilled water. 
10 ml NP-40 [10%], 0.1 g SDS, 3 ml NaCl [5M], 5 ml Tris-HCl [1M], 200 µl EDTA [1mM], 
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